Robust Control of a Brain-Persisting Parasite through MHC I Presentation by Infected Neurons

Anna Salvioni, Marcy Belloy, Aurore Lebourg, Emilie Bassot, Vincent Cantaloube-Ferrieu, Virginie Vasseur, Sophie Blanié, Roland Liblau, Elsa Suberbielle, Ellen Robey, et al.

▶ **To cite this version:**

Anna Salvioni, Marcy Belloy, Aurore Lebourg, Emilie Bassot, Vincent Cantaloube-Ferrieu, et al.. Robust Control of a Brain-Persisting Parasite through MHC I Presentation by Infected Neurons. Cell Reports, 2019, 27 (11), pp.3254-3268.e8. 10.1016/j.celrep.2019.05.051 . hal-02374306

HAL Id: hal-02374306
https://hal.science/hal-02374306

Submitted on 25 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Version of Record: https://www.sciencedirect.com/science/article/pii/S2211124719306801
Manuscript_4c44d90a8b8f4c3d2c41d91e506f16cc

Robust control of a brain-persisting parasite through MHC I presentation by infected neurons

Anna Salvioni[1], Marcy Belloy[1], Aurore Lebourg[1], Emilie Bassot[1], Vincent Cantaloube-Ferrieu[1], Virginie Vasseur[1], Sophie Blanié[1], Roland S. Liblau[1], Elsa Suberbielle[1], Ellen A. Robey[2], Nicolas Blanchard[1*]

[1] Center for Pathophysiology Toulouse-Purpan (CPTP), INSERM, CNRS, University of Toulouse, 31024 Toulouse, France

[2] Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA

* Address correspondence to Nicolas Blanchard, nicolas.blanchard@inserm.fr

CPTP INSERM U1043 - CHU Purpan - BP3028 – 31024 Toulouse Cedex 3 – France

Lead contact: Nicolas Blanchard, nicolas.blanchard@inserm.fr

© 2019 published by Elsevier. This manuscript is made available under the CC BY NC user license
https://creativecommons.org/licenses/by-nc/4.0/

Summary

Control of central nervous system (CNS) pathogens by CD8 T cells is key to avoid fatal neuroinflammation. Yet the modalities of MHC I presentation in the brain are poorly understood. Here we analyze the antigen presentation mechanisms underlying CD8 T cell-mediated control of the *Toxoplasma gondii* parasite in the CNS. We show that MHC I presentation of an efficiently processed model antigen (GRA6-OVA), even when not expressed in the bradyzoite stage, reduces cyst burden and dampens encephalitis in C57BL/6 mice. Antigen presentation assays with infected primary neurons reveal a correlation between lower MHC I presentation of tachyzoite antigens by neurons and poor parasite control *in vivo*. Using conditional MHC I-deficient mice, we find that neuronal MHC I presentation is required for robust restriction of *T. gondii* in the CNS during chronic phase, showing the importance of MHC I presentation by CNS neurons in the control of a prevalent brain pathogen.

Introduction

The brain is endowed with specialized innate and adaptive immune mechanisms that ensure both the detection and mitigation of neurotropic infections (Klein and Hunter, 2017; Russo and McGavern, 2015) but some pathogens can chronically reside within the central nervous system (CNS). Accumulating evidence point to intricate links between neuroinflammation and the development of neurodegenerative diseases (Colonna and Butovsky, 2017; Heneka et al., 2015). By eliciting various degrees of inflammation, chronically persisting CNS pathogens are likely to influence brain processes, including age-related cognitive dysfunctions (Cabral et al., 2017; McManus and Heneka, 2017; Mohle et al., 2016). A better understanding of the mechanisms by which immune components of the CNS, such as CD8 T cells, detect and control persisting microorganisms is needed not only to improve containment of these pathogens but also to potentially alleviate detrimental effects of chronic infections on brain functions.

The protozoan intracellular parasite *Toxoplasma gondii* is a widespread foodborne pathogen (Guo et al., 2016), which commonly infects humans. Due to the lack of an effective drug targeting its encysted bradyzoite stage, this parasite cannot be cleared from the brain. Hence, with a worldwide seroprevalence of ~30% (Pappas et al., 2009) that can reach up to 50% in certain countries (Wilking et al., 2016), *T. gondii* is thought to reside in the brains of more than 2 billion individuals. Following dissemination of the rapidly-dividing tachyzoites in the host, the parasite converts into slower-growing bradyzoites, which chronically persist within cysts in muscles and in the CNS (Ferguson and Hutchison, 1987). In the CNS, multiple resident cell types may be in contact with tachyzoites but neurons are the only cells supporting the development of cysts (Cabral et al., 2016; Melzer et al., 2010), which are mostly found within intact host cells (Ferguson and Hutchison, 1987).

The clinical outcome of *T. gondii* infection critically depends on the host immune status and more specifically on a fully functional T cell compartment. In immunocompetent humans, acute infection remains mildly symptomatic but chronic presence of *T. gondii* in the brain (referred to as latent toxoplasmosis) has been associated with neuropsychiatric disorders, such as schizophrenia (Torrey and Yolken, 2003) and cognitive changes (Stock et al., 2017), although

conflicting data exist on this question (Perry et al., 2016; Wyman et al., 2017). In rodents, which are natural hosts of *T. gondii*, the parasite has been reported to influence the course of neurodegenerative disorders (Cabral et al., 2017; Mohle et al., 2016) and to cause major behavioral modifications (Vyas, 2015). In case of T cell lymphopenia or sub-optimal function (e.g. due to HIV/AIDS or immune suppressive treatment), individuals become at risk of developing *T. gondii* encephalitis (TE), a fatal neuroinflammatory disease that is still common among HIV-infected people (Ondounda et al., 2016). TE is characterized by high cyst burden, tachyzoite replication foci in the CNS, massive immune cell influx, activation of recruited and local myeloid cells and cerebral tissue damage (Parlog et al., 2014). TE is also associated with activation and exhaustion of CD4 T cells, leading to functional attrition of CD8 T cells (Hwang et al., 2016).

Mouse studies have highlighted a variety of innate immune mechanisms that can contribute to parasite control in the brain. These include the production of pro-inflammatory mediators by innate mononuclear cells (Biswas et al., 2015; Sa et al., 2015) and neutrophils (Biswas et al., 2017), as well as anti-microbial pathways triggered by IFNγ/STAT1 in astrocytes (Hidano et al., 2016). Yet, these processes are typically not sufficient to prevent TE pathogenesis. In contrast, CD8 T cells and MHC I, in particular the H-2 L^d MHC I allele, are pivotal to drive robust and durable brain parasite control and to dampen encephalitis, a status known as TE resistance (Blanchard et al., 2008; Brown et al., 1995). Consequently, C57BL/6 mice, which are devoid of H-2 L^d, are a good model to study the pathogenesis of *T. gondii* encephalitis while mice expressing H-2 L^d (e.g. BALB/c or congenic B6.H-2^d mice) are TE-resistant (Blanchard et al., 2015). In mice bearing the H-2^d MHC haplotype, protection from TE relies on the induction of CD8 T cells specific for an immunodominant L^d-restricted peptide that is efficiently processed from the *T. gondii*-secreted GRA6 protein in infected macrophages and dendritic cells (DC) (Blanchard et al., 2008; Feliu et al., 2013). This protective response is maintained without a contraction phase, by continuous production of effector CD8 T cells *via* a proliferative, antigen-dependent population, displaying a memory-effector hybrid phenotype (Chu et al., 2016). While induction of GRA6-specific peripheral CD8 T cell responses in the periphery is a clear

prerequisite to enable robust parasite control in the brain (Feliu et al., 2013), the determinants underlying CD8-mediated surveillance of *T. gondii* in the CNS in the context of TE resistance remain ill-defined.

To address this question without modifying the endogenous GRA6 protein, which plays a role in cystogenesis (Fox et al., 2011), we created transgenic parasites ectopically expressing a model antigen composed of the H-2 K^b-restricted OVA-derived SIINFEKL epitope in fusion with the C-terminus of GRA6, a known immunogenic position (Feliu et al., 2013). Compared to parasites expressing the same SIINFEKL epitope within a different source antigen (vacOVA), C57BL/6 mice infected with the GRA6-OVA-expressing parasites displayed limited brain inflammation. Using a promoter restricting expression of the GRA6-OVA antigen to tachyzoites, we showed that CD8 T cell recognition of this antigen at the tachyzoite stage is enough to ensure parasite restriction in the brain. Measurements of antigen presentation by primary neuronal cultures infected with parasites leading to TE (vacOVA) or to a reduced CNS inflammation (GRA6-OVA) suggested the implication of neuronal MHC I presentation in the control of brain parasite load. To formally address this possibility, we developed a mouse model enabling selective ablation of the H-2 L^d allele (naturally conferring resistance to TE) in neurons. Our results revealed that although neuronal MHC I presentation is dispensable for CNS accumulation of *T. gondii*-specific CD8 T cells, it is critical for durable parasite control.

Results

A CD8 T cell-dependent TE-resistant model in C57BL/6 mice based on GRA6-OVA expression

To study how CD8 T cell-mediated detection and restriction of *T. gondii* in the CNS are achieved, we sought to create a C57BL/6-based model in which parasites expressing a tractable CD8 T cell model antigen would be efficiently or poorly controlled at chronic phase, leading to limited vs. active brain inflammation and thereby mimicking *T. gondii* latency *vs.* encephalitis. Since CD8 T cell responses specific for the GRA6-derived HPGSVNEFDF (HF10) epitope are pivotal for resistance to *T. gondii* encephalitis in H-2 L^{d+} mice (Blanchard et al., 2008; Feliu et al., 2013) and since GRA6 C-terminus is a preferential location for antigenicity (Buaillon et al., 2017; Feliu et al., 2013), we reasoned that the addition of the H-2 K^{b}-restricted chicken ovalbumin (OVA)-derived SIINFEKL model epitope to the C-terminus of GRA6 may protect C57BL/6 mice from the CNS inflammation that is typically observed after infection by type II parasites. To test this hypothesis, we generated type II parasites (Tomato^{+} Pru) expressing the GRA6-OVA model antigen. In order to preserve the final antigen processing steps, the OVA-derived SIINFEKL peptide was flanked by 5 amino acids that are naturally present in OVA (**Fig. 1a**). In parallel, we took advantage of a previously described (Schaeffer et al., 2009) Tomato^{+} Pru strain that expresses the SIINFEKL epitope embedded in a different dense granule-secreted antigen: the vacuolar SAG1ΔGPI-OVA protein (abbreviated here as vacOVA) (**Fig. 1a**). The resulting parasites are designated as *Tg*.pGRA6/GRA6-OVA and *Tg*.pTUB/vacOVA, respectively. In line with the known dual-stage activity of the tubulin and GRA6 promoters respectively controlling the expression of vacOVA and GRA6-OVA, these two antigenic constructs were detected both in tachyzoites and bradyzoites (Schaeffer et al., 2009) (**Fig. 1a**). To ensure that the comparison of these two transgenic parasites was valid, we evaluated the *in vivo* dissemination, access to the brain and CD8 T cell responses elicited in the course of acute toxoplasmosis. Ten days post-infection, comparable OVA-specific CD8 T cell responses were induced in the spleen by both strains, which disseminated in the spleen and, even more efficiently than the parental strain, in the brain (**Sup. Fig. 1a, b, c, d**). Yet 3 weeks post-infection, i.e. at the beginning of chronic stage, the *Tg*.pGRA6/GRA6-OVA parasites were more robustly restricted in the CNS than the

Tg.pTUB/vacOVA parasites. Such a difference was observed in H-2^b (K^b-positive) C57BL/6, which develop prominent SIINFEKL-specific CD8 T cell responses in the CNS (**Fig. 4d, e**), but not in H-2^k (K^b-negative) CBA mice (**Fig. 1b, c, d and Fig S1e, f, g**). As CBA mice are unable to present the SIINFEKL peptide, these data show (i) that the *in vivo* fitness of the *Tg*.pGRA6/GRA6-OVA is not altered and (ii) that the beneficial impact of GRA6-OVA on CNS parasite control in C57BL/6 mice is likely linked to H-$2K^b$-restricted CD8 T cell responses.

Next we assessed whether the lower load of *Tg*.pGRA6/GRA6-OVA in the CNS indeed correlated with reduced brain inflammation. Besides a high cyst burden, the encephalitis caused by *T. gondii* is typically characterized by foci of tachyzoite replication, activation of brain-resident microglia and macrophages, infiltrates of activated lymphocytes and myeloid cells comprising inflammatory monocytes and DC (Biswas et al., 2015; Blanchard et al., 2015; Hwang et al., 2016; John et al., 2011; O'Brien et al., 2019; O'Brien et al., 2017; Zhang et al., 2014). As a reflection of the myeloid cell infiltrate, the relative abundance of brain-infiltrating $CD11b^+$ $CD45^{hi}$ over brain-resident microglia (typically characterized as $CD11b^+$ $CD45^{int}$ at steady-state), was reduced in mice infected with parasites expressing GRA6-OVA (**Fig. 1e, f**). Although the surface levels of MHC II and CD86 on $CD11b^+$ $CD45^{int}$ microglia did not dramatically differ between the infected groups at this time point (**Fig S1h, i, j, k**), $Iba1^+$ cells were found accumulated in foci in the cortex of mice infected with the parental or *Tg*.pTUB/vacOVA parasites (**Fig. 1g**). There was no substantial difference in the level of CD86 expression on $CD11b^+$ $Ly6C^{hi}$ inflammatory monocytes across the infected groups (**Fig S1l**) but the infiltration of inflammatory $Ly6C^{hi}$ monocytes was decreased in the brains *Tg*.pGRA6/GRA6-OVA-infected mice (**Fig. 1h**), which also displayed the lowest proportion of monocyte-derived $MHCII^+$ DC (**Fig. 1i**). At last, less activated IFNγ-producing CD4 T cells were found in brains from *Tg*.pGRA6/GRA6-OVA-infected mice (**Fig. 1j**).

Together, these results indicate that, in comparison to the parental strain or to vacOVA-expressing parasites, infection with GRA6-OVA-expressing type II *T. gondii* elicits efficient parasite control in the CNS and reduced CNS inflammation. They establish a useful model to study TE resistance in C57BL/6 mice.

Comparable OVA-specific CD8 T cell responses elicited by GRA6-OVA when expressed by both parasite stages or when restricted to tachyzoites

Depending on the time post-infection (early dissemination *vs.* chronic stage) and the immunological context examined (effective *vs.* poor parasite control), the CNS tissue can harbor varying numbers of *T. gondii* tachyzoites and bradyzoites (Bhadra et al., 2013). In order to examine which parasite stage(s) is/are efficiently held in check by CD8 T cells in the CNS in the context of latent toxoplasmosis, we generated parasites where GRA6-OVA expression was restricted to tachyzoites. To this aim, we drove expression of the GRA6-OVA antigen with the SAG1 promoter, which is active only at the tachyzoite stage, thereby generating the *Tg*.pSAG1/GRA6-OVA strain (**Fig. 2a**). Using two complementary assays, we confirmed that GRA6-OVA was indeed shut-down in *Tg*.pSAG1/GRA6-OVA bradyzoites. First, tachyzoite-infected fibroblasts were treated with apicidin, a histone deacetylase inhibitor which upregulates several genes involved in bradyzoite conversion (Bougdour et al., 2009; Boyle et al., 2006). We observed by Western blot that GRA6-OVA expression was lost in apidicin-treated *Tg*.pSAG1/GRA6-OVA bradyzoites (**Fig. S2a, b**). Because only part of the bradyzoite differentiation program is mimicked by apicidin treatment (Bougdour et al., 2009), we also evaluated expression of the respective antigenic constructs in *ex vivo* isolated *bona fide* cysts. GRA6-OVA could be visualized in *Tg*.pGRA6/GRA6-OVA cysts and, confirming the *in vitro* data, it was not detectable in *Tg*.pSAG1/GRA6-OVA cysts (**Fig. 2b**).

Having validated the stage expression profile of these two antigenic constructs, we analyzed MHC I presentation, CD8 T cell responses and dissemination to the brain during acute phase. Using LacZ-inducible reporter CD8 T cell hybridomas that specifically respond to the K^b-SIINFEKL MHC-peptide complexes (B3Z), we observed an equivalent presentation of the SIINFEKL peptide by DC infected with tachyzoites, regardless of the promoter used (**Fig. 2c**), which was consistent with a similar induction of OVA-specific CD8 T cell responses in the spleen 10 days post infection (**Fig. S2c, d**). In addition, in this context, initial parasite invasion of the brain was not substantially altered by the presence of GRA6-OVA compared to the parental strain (**Fig. S2e**).

We then proceeded to analyze CD8 T cell responses, parasite burden and CNS inflammation at chronic phase. We chose to perform the analyses at late chronic phase, i.e. 2 months post-infection, to limit the potential effects of pSAG1/GRA6-OVA residual expression that would be expected in the early days of chronic phase, when bradyzoites have converted only recently. Whether or not GRA6-OVA was expressed in bradyzoites, both strains elicited comparable CD8 T cell responses to the SIINFEKL peptide in the spleen and brain (**Fig. 2d, e, f, h, i**). CD8 T cells specific for another K^b-restricted peptide, the Tgd057-derived SVLAFRRL epitope, were found in similar proportions in the 3 groups in the spleen and were slightly more abundant in the brains of mice infected with the parental *Tg.*GFP (**Fig. 2e, g, h, j**). In conclusion, CD8 T cell responses developing against a *T. gondii* tachyzoite-restricted antigen are maintained throughout chronic infection, even in the absence of antigen expression by bradyzoites.

Tachyzoite-restricted GRA6-OVA expression is sufficient to provide robust CNS parasite control and to dampen TE

We next assessed the impact of tachyzoite-restricted GRA6-OVA expression on brain parasite control and TE pathogenesis (**Fig. 3a**). Compared to the parental strain, we observed a major reduction in brain cysts (**Fig. 3b**) and parasite DNA (**Fig. 3c**) in C57BL/6 mice infected with *T. gondii* expressing GRA6-OVA independently from the promoter. Consistent with brain parasite control being primarily mediated by K^b-OVA-specific CD8 responses (see Fig. 1d), parasite burdens were similar in chronically infected TE-susceptible H-2^k CBA mice (**Fig. 3d**). In order to assess TE pathogenesis, we evaluated the CNS immune infiltration and activation of myeloid and CD4 T cells. Regardless of the promoter, mice infected with GRA6-OVA-expressing strains displayed a lower ratio of $CD11b^+$ $CD45^{hi}$ inflammatory myeloid cells over $CD11b^+$ $CD45^{int}$ microglia (**Fig. 3e, f**) and microglial populations were less activated, as evidenced by reduced CD86 and MHC II surface expression (**Fig. 3g, h**). We observed a less pronounced accumulation of $CD11b^+$ $Ly6C^{hi}$ inflammatory monocytes (**Fig. 3i**), which displayed a lower, though not significant, level of CD86 expression (**Fig. 3j**) and among which there were fewer differentiated MHC II^+ DC (**Fig. 3k**). At last, these brains contained less IFNγ-producing CD4 T cells (**Fig. 3l**).

These results show that C57BL/6 mice infected with *Tg*.pGRA6/GRA6-OVA and *Tg*.pSAG1/GRA6-OVA have reduced brain inflammation, in contrast to mice infected with parental *Tg.*GFP.

Altogether, this set of data indicates that CD8 T cell recognition of an efficiently processed tachyzoite-derived antigen is sufficient to provide effective parasite control in the CNS, thereby limiting the development of TE.

Limited TE development conferred by GRA6-OVA expression correlates with efficient neuronal MHC I presentation

We next sought to gain further insights into the modalities of MHC I presentation within the CNS, in particular regarding the nature of the antigen-presenting cells that determine the pathogenesis of TE. To this aim, we took advantage of the *Tg*.pTUB/vacOVA and *Tg*.pGRA6/GRA6-OVA parasite strains described in Figure 1, which express the same CD8 T cell epitope embedded in differentially protective source antigens, leading to varying levels of parasite control and CNS inflammation. We first interrogated whether the poor containment of *Tg*.pTUB/vacOVA parasites compared to *Tg*.pGRA6/GRA6-OVA could be due to improper recruitment and activation of OVA-specific CD8 T cells in the cerebral tissue. In contrast to the experiments in which the GRA6-OVA antigen was restricted to tachyzoites (see Fig. 2 and 3), there was no concern about residual antigen expression in the early chronic phase. Furthermore, the differences in brain parasite burden and inflammation of Figure 1 were observed at 3 weeks post-infection. Therefore, we assessed the abundance, specificity and effector functions of splenic and brain-infiltrating CD8 T cells 3 weeks post-infection (**Fig. 4a**). In the spleen, substantial SIINFEKL-specific CD8 T cells were elicited by both GRA6-OVA- and vacOVA-expressing parasites, with a slightly higher magnitude in the context of *Tg*.pGRA6/GRA6-OVA infection **(Fig. 4b, c)**. In the brain, the numbers of K^b-SIINFEKL dextramer$^+$ CD8 T cells and of IFNγ-producing CD8 T cells after SIINFEKL peptide restimulation were similar between *Tg*.pTUB/vacOVA and *Tg*.pGRA6/GRA6-OVA-infected mice (**Fig. 4d, e**). Analysis of the effector potential of OVA-specific CD8 T cells following *in vitro* peptide restimulation showed that vacOVA-expressing parasites in fact led to larger quantities of triple-producing IFNγ$^+$ TNF$^+$ granzyme B$^+$ CD8 T cells (**Fig. 4f**). This may be related to the higher parasite burden observed in

this setting. A more abundant antigenic material could, *via* MHC I presentation by local APC, accelerate CD8 T cell differentiation into effector cells. In conclusion however, poor control of vacOVA-expressing parasites is not due to defective infiltration or impaired effector differentiation of *T. gondii*-specific CD8 T cells in the infected CNS. On this ground, we hypothesized that what may be subpar in the vacOVA context is the recognition of infected target cells by CD8 T cells.

Neurons being the most predominant host cells for *T. gondii* in the CNS (Cabral et al., 2016; Ferguson and Hutchison, 1987; Melzer et al., 2010), we speculated that inefficient neuronal MHC I presentation of vacOVA compared to GRA6-OVA may underlie impaired parasite control. To test this possibility, we set out to probe antigen presentation by primary neurons infected with *Tg*.pTUB/vacOVA and *Tg*.pGRA6/GRA6-OVA tachyzoites using the SIINFEKL-specific LacZ-inducible B3Z reporter CD8 T cell hybridomas (**Fig. 5a**). First, we optimized neuronal culture conditions to ensure that the proportion of glial cells was minimal because these are potent antigen-presenting cells that may blur the interpretation of the assay (**Fig. S3a, b**). We also verified that 24 h post-infection, > 95% of the *T. gondii* tachyzoite-containing vacuoles were harbored in neurons (**Fig. S3c**) and that there were no differences in neuronal infection rates between the two parasite strains (**Fig. 5b, c**). Antigen presentation measurements revealed that the GRA6-OVA antigen was processed and presented by H-2K^{b} to the reporter CD8 T cells more efficiently than the vacOVA antigen (**Fig. 5d**).

These data support the notion that failure to control vacOVA-expressing parasites in the CNS may be related to sub-optimal MHC I presentation of *T. gondii* tachyzoite antigens by infected neurons.

MHC I L^{d} selective ablation in neurons hampers control of parasite load in the CNS

To formally address the *in vivo* requirement for neuronal MHC I antigen presentation in the control of CNS parasites, we designed a Cre-loxP-based conditional deletion approach. Because MHC I molecules play important functions during brain development and plasticity (Corriveau et al., 1998; Elmer and McAllister, 2012; Huh et al., 2000), we reasoned that it would be

appropriate to leave the endogenous C57BL/6 MHC I locus intact while introducing a floxed version of H-2 L^d, the allele that was originally associated with TE resistance (Blanchard et al., 2008; Brown et al., 1995). We thus generated transgenic B6.L^dLox mice expressing a floxed L^d gene, in which exons 1 to 3 are flanked by LoxP sites (**Fig. 6a**). As expected, T cells, B cells and DC in the spleen of B6.L^dLox mice displayed K^b levels that were analogous to C57BL/6 mice (**Fig. 6b**). Surface expression of L^d in B6.L^dLox mice was slightly reduced compared to B6.H-2^d congenic mice, which naturally express H-2 L^d (**Fig. 6c**) but despite this, B6.L^dLox and B6.H-2^d mice mounted robust CD8 T cell responses to the L^d-restricted *T. gondii* GRA6-derived HF10 peptide in the spleen and brain (**Fig. 6d, e, f**). Accordingly, compared to C57BL/6 mice, B6.L^dLox mice were potent in their ability to control brain *T. gondii* during chronic infection (**Fig. 6g**).

In order to selectively eliminate L^d from neurons, we bred B6.L^dLox with B6.CamKIIα-iCre mice, which express the Cre recombinase in all excitatory glutamatergic neurons of the CNS (forebrain, hippocampus, olfactory lobe and scattered cells in hypothalamus) (Casanova et al., 2001; Wang et al., 2013). In Cre^+ mice, CamKIIα^+ neurons should express only K^b and D^b whereas all other cells should express K^b, D^b and L^d (**Fig. 6h**). The level of L^d on the surface of leukocytes isolated from infected brains was indeed comparable regardless of Cre expression (**Fig. S4a**). In addition, as shown in primary co-cultures of neuronal and glial cells from CamKIIα-Cre^+ *vs.* CamKIIα-Cre^- mice, L^d expression was significantly reduced in Cre^+ neurons while it was not changed in Cre^+ glial cells (**Fig. S4b, c**). To monitor parasite-specific CD8 T cell responses, we infected mice with a *T. gondii* strain that naturally carries the endogenous GRA6 and Tgd057 proteins but is devoid of the OVA antigen. Effector CD8 T cell responses specific for the GRA6-derived L^d-restricted HPGSVNEFDF peptide and the Tgd057-derived K^b-restricted SVLAFRRL peptide were elicited similarly in the periphery of Cre^+ and Cre^- mice (**Fig. S5a, b, c**). Parasite dissemination in the spleen, peritoneum and brain throughout acute infection was also comparable in the presence or absence of L^d on neurons (**Fig. S5d, e, f**). To evaluate the impact of L^d neuronal deletion during chronic infection, we infected mice *per os* with the 76K unmanipulated strain, akin to what occurs during natural infection. On week 3 post-infection, there was a >10-fold increase in brain parasite burden in mice devoid of L^d in neurons, reflected

297 both by elevated cyst numbers (**Fig. 6i, j**) and parasite DNA (**Fig. 6k**). Brain parasite control in
298 Cre^+ mice was as poor as that observed in chronically infected TE-susceptible C57BL/6 mice (**Fig.**
299 **6j, k**), indicating that the selective absence of L^d on neurons critically impairs the ability of local
300 CD8 T cells to restrict CNS parasites. To check if L^d deficiency in neurons impeded the
301 development of cerebral CD8 T cell responses, we quantified the numbers of total CD8 T cells
302 and GRA6-specific CD8 T cells in chronically infected brains. Absence of L^d in neurons did not
303 abrogate the infiltration of total CD8 T cells (**Fig. 6l**), nor did it preclude the accumulation of
304 IFNγ-producing GRA6-specific CD8 T cells (**Fig. 6m**). Evaluation of the ratio of inflammatory
305 myeloid cells over microglia, of the activation status of microglia and of the IFNγ-producing CD4
306 T cells in the CNS did not reveal substantial differences between Cre^- and Cre^+ animals (**Fig. S6**),
307 suggesting that at 3 weeks post-infection, neuronal presentation of *T. gondii* antigens by L^d
308 plays a limited role in regulating CNS inflammation. Altogether, our findings establish that
309 efficient MHC I presentation of immunodominant *T. gondii* antigen by tachyzoite-infected
310 neurons is dispensable for the accumulation of CD8 T cells in the CNS but is a prerequisite for
311 sustained parasite control by CD8 T cells in this organ.

312

Discussion

Combining transgenic *T. gondii* parasites, antigen presentation assays with primary neurons and a mouse model of conditional MHC I deletion, our data support a model whereby the efficacy of CD8 T cell-mediated surveillance of tachyzoite-infected neurons determines the severity of CNS inflammation. Notably, C57BL/6 mice infected with GRA6-OVA-expressing parasites durably control the parasite in the CNS and show limited encephalitis throughout late chronic infection.

Our work sheds light on the stage specificity of CD8 T cell-mediated surveillance of *T. gondii* in the CNS. In the context of TE development, two-photon laser scanning microscopy imaging of infected brains previously revealed that CD8 T cells contact granuloma-like structures containing tachyzoites and that they interact in a cognate manner with individual $CD11b^+$ or $CD11c^+$ antigen-presenting cells (APC) that are not necessarily infected (John et al., 2011; Schaeffer et al., 2009). It was also found that CD8 T cells largely ignore neurons harboring cysts (Schaeffer et al., 2009), in line with the notion that, as 'dormant' persisting structures, cysts must be impervious to host immunity. However bradyzoites within tissue cysts are dynamic and replicative entities (Watts et al., 2015) and intra-neuronal cysts contain up to thousands of bradyzoites that continue to express and secrete a number of proteins, some of which are major CD8 T cell targets (e.g. ROP7 (Frickel et al., 2008) and GRA6). Therefore, in the context of latent toxoplasmosis, a different scenario may prevail whereby CD8 T cells could directly recognize and eliminate cysts. In accordance, it was reported in a TE reactivation model in which immunodeficient BALB/c mice are treated with sulfadiazine, that following adoptive transfer, total splenic CD8 T cells isolated from chronically infected mice could reduce cyst count through a perforin-dependent, IFNγ-independent, *modus operandi* (Suzuki et al., 2010). Here, in the course of primary infection of an immunocompetent host, we report that *T. gondii*-infected neurons are able to process tachyzoite antigens and to display antigenic fragments *via* MHC I for CD8 T cell recognition. This is then sufficient to restrict brain cyst load up to 2 months post-infection, stressing the notion that CD8 T cell recognition of tachyzoite-derived antigens is a prominent driver to limit the development of TE. In this model, we hypothesize that antigenic peptides are displayed by neuronal MHC I as soon as a neuron gets infected by a tachyzoite and

that this is enough to trigger cytotoxic T lymphocyte (CTL)-mediated containment of the parasite invader. An interesting implication is that in the context of TE resistance, the parasites are controlled 'from the beginning' (as tachyzoites) and that bradyzoite conversion only minimally occurs. It will now be essential to determine by which mechanisms bradyzoites actively escape CD8 T cell surveillance, including in the context of the robust CD8 T cell responses leading to reduced encephalitis. Current drugs are ineffective on cysts, hence being able to restore presentation of bradyzoite antigens in order to boost cyst clearance by CD8 T cells could ultimately open new therapeutic avenues for at-risk individuals.

Another asset of our work is the creation of a mouse model to genetically test the importance of neuronal MHC I presentation in the control of *T. gondii* within the CNS. *In vitro* validation of the B6.L^dLox model using primary neuronal cultures showed a selective reduction of L^d in neurons compared to glial cells, but not a complete loss. The residual expression of L^d observed in Cre^+ neurons in this assay may be linked to the late and/or heterogenous expression of the CamKIIα promoter in *in vitro* cultures as well as to the half-life of the L^d protein following Cre-mediated excision. Since our attempts to detect L^d directly on brain sections have not been successful, one cannot exclude that a fraction of CamK-Cre^+ neurons still retain L^d expression *in vivo* following infection. Regardless, we found major consequences on parasite burden, indicating that MHC I presentation by CamKα^+ excitatory glutamatergic neurons plays an important role for the control of *T. gondii* in the CNS. Although initially controversial, it is now indisputable that MHC I molecules are expressed by neurons, at the surface of both axons and dendrites (Elmer and McAllister, 2012). Neuronal MHC I plays essential functions during brain development by restricting the activity-dependent plasticity of connections (Huh et al., 2000) and negatively regulating synaptic density (Glynn et al., 2011). In addition, several lines of evidence support the notion that neuronal MHC I can present antigenic peptides and activate CD8 T cells. Expression of a neo-antigen by neuronal subtypes, like the orexinergic neurons (Bernard-Valnet et al., 2016) or Purkinje cells (Yshii et al., 2016), was associated with CTL granule polarization and destruction of the neuron subset expressing the antigen. In viral infections such as with Lymphocytic Choriomeningitis Virus (LCMV) (Kreutzfeldt et al., 2013; Rall

et al., 1995), Theiler's murine encephalomyelitis virus (McDole et al., 2010) and Borna disease virus (Chevalier et al., 2011), CTL have been shown to interact with infected neurons in a MHC I- and antigen-specific manner. Our work now demonstrates the essentiality of MHC I presentation for effective CD8 T cell control of a widespread, non-viral, neurotropic pathogen.

What may be the outcome of neuronal MHC I presentation on neuron function? In certain contexts, contacts of neurons with CTL lead to neuron killing (Bernard-Valnet et al., 2016; Cebrian et al., 2014) but in other situations, they induce more subtle morphological changes, such as an increase in membrane permeability (Chevalier et al., 2011), synaptic stripping (Di Liberto et al., 2018) or a loss of axon integrity (Sauer et al., 2013), without triggering immediate apoptosis. An alteration of electrical properties has also been reported (Meuth et al., 2009). Future investigations should be undertaken to address whether cognate contacts between CTL and *T. gondii*-infected neurons could result in alterations of the electrical activity of individual neurons or integrated neuronal networks (Casanova et al., 2018). These experiments may ultimately shed light on some mechanisms behind the behavioral alterations induced by *T. gondii*.

Importantly, our study does not rule out important contributions from other CNS-resident cells in regulating the course of toxoplasmosis *via* MHC I presentation of pathogen fragments. The main impact of L^d deletion in neurons is to hamper parasite control but the consequences on brain inflammation appear more modest. It does not seem so surprising since regardless of the Cre status, L^d presentation is expected to remain intact in all other brain-resident and -infiltrating populations, which are likely to be critical for T cell/myeloid cell infiltration. Chief among these are microglia, which are potent antigen-presenting cells involved in regulating effector and memory CD8 T cells that have reached the CNS (Colonna and Butovsky, 2017). In chronically LCMV-infected mice, microglia act as a viral reservoir and they can be prompted to present viral antigens that promote viral purge by CD8 T cells (Herz et al., 2015). In *T. gondii*-infected CNS, microglia are activated in the vicinity of *T. gondii* replication foci during TE (Zhang et al., 2014). Since L^d elimination from neurons only modestly impacted CD8 T cell accumulation, it is tempting to speculate that L^d deletion from microglia would instead

397 profoundly disrupt CD8 T cell infiltration and/or memory CD8 T cell formation in the brain.
398 Astrocytes is another cell type, which antigen-presenting function would deserve further
399 scrutiny (Wilson and Hunter, 2004). T cells may encounter astrocytes either in the parenchyma
400 or when crossing the blood-brain barrier endothelium that is surrounded by astrocytic endfeet.
401 Studies in viral infections uncovered a possible interplay between astrocytes and CD8 T cells (Xie
402 and Yang, 2015). Thanks to the above-described mouse model and to a recently published
403 floxed K^b system (Malo et al., 2018), it will now be possible to explore the role(s) of MHC I
404 presentation by CNS-resident cells in homeostasis and disease. In the case of chronic *T. gondii*
405 infection, these models may be useful to better understand how brain function is impacted by
406 this widespread parasite.

407

408

Acknowledgments

F. L'Faqihi-Olive, V. Duplan-Eche, A.-L. Iscache, L. de la Fuente for technical assistance at the CPTP-Inserm U1043 flow cytometry facility ; S. Allart, A. Canivet-Laffitte, D. Daviaud for technical assistance at the CPTP-Inserm U1043 imaging facility ; G. Tavernier and Y. Barreira at INSERM UMS006-CREFRE for the generation of the B6.L^{d}Lox mice, R. Balouzat and the zootechnicians at INSERM UMS006-CREFRE mouse facility ; the Blanchard and Robey teams for help and discussions ; M.-F. Cesbron-Delauw for the anti-GRA1 and anti-GRA2 antibodies, H. Acha-Orbea for the MutuDC, D. Buzoni-Gatel for the 76K parasites, S.-K. Kim, J. Boyle and J. Boothroyd for the GFP^{+} Pru tachyzoites ; T. Hansen for the pL^{d}4 plasmid ; G. Schutz for the B6.CamKIIα-iCre mice ; I. Cebrian and D. Dunia for critical reading of the manuscript.

This work was supported by 'Institut National de la Santé et de la Recherche Médicale', Idex Toulouse 'Attractivity Chair' Program (to ER and NB), Human Frontier Science Program Organization (CDA00047/2011 to NB), PIA PARAFRAP Consortium (ANR-11-LABX0024 to NB), PIA ANINFIMIP equipment (ANR-11-EQPX-0003 to NB), Agence Nationale pour la Recherche (ANR-18-CE15-0015 to NB and ES), 'Fondation pour la Recherche Médicale' to AS (FDT20170436953).

Author Contributions

Conceived and designed the experiments: AS, MB, ES, SB, EAR, NB. Performed the experiments: AS, MB, ES, AL, EB, VCF, VV, SB. Analyzed the data: AS, MB, ES, AL, EB, VCF, VV, SB, RSL, EAR, NB. Wrote the paper: NB with help of coauthors.

Declaration of interests

The authors declare no competing interests.

Main Figure Titles and Legends

Figure 1. Expression of GRA6-OVA antigen by *T. gondii* leads to efficient parasite control and lower CNS inflammation

(a) Schematics of GRA6-OVA and vacOVA antigenic constructs expressed in the Tomato^{+} Prugnaud (Pru) parental strain. GRA6-OVA: fusion protein between GRA6(II) and LEQLE-SIINFEKL sequence, driven by the GRA6 promoter. vacOVA: fusion protein between SAG1ΔGPI and amino acids [140-386] of OVA, which contain the LEQLE-SIINFEKL sequence, driven by the tubulin promoter. Representative immunofluorescent images of a parasitophorous vacuole and an *ex vivo* cyst to illustrate activity of both promoters in tachyzoites and bradyzoites. Red: intrinsic Tomato fluorescence. Green: anti-SIINFEKL staining for GRA6-OVA, anti-full length OVA staining for vacOVA. **(b)** Schematics of experimental infections in mice infected i.p. with either of the 3 parasite strains. Analyses of brain parasite load and immunological status 3 weeks post-infection. **(c, d)** Number of brain cysts enumerated microscopically (mean +/- SEM) in H-2^{b} C57BL/6 mice **(c)** and H-2^{k} CBA mice **(d)**. **(e)** Flow cytometry gating strategy to analyze myeloid cells in the CNS. **(f)** Analysis of inflammatory CD45^{hi} CD11b^{+} myeloid cells and resident CD45^{int} CD11b^{+} ('microglia') cells. Numbers on the representative contour plots show the mean percentage +/- SD of each subset out of single live Ly6G^{-} NK1.1^{-} cells. Graph shows the ratio (mean +/- SEM) of CD45^{hi} over CD45^{int} cells. **(g)** Representative brain cortical sections from uninfected and infected mice, stained for Iba1. Scale bar: 100 μm for 5X images, 25 μm for 20X images **(h)** Analysis of Ly6C^{hi} inflammatory monocytes. Numbers on the representative contour plots show the mean percentage +/- SD of Ly6C^{hi} cells out of single live Ly6G^{-} NK1.1^{-} CD45^{hi} CD11b^{+} cells. Graph shows absolute numbers (mean +/- SEM). **(i)** Proportion of MHC II^{+} cells (DC) among Ly6C^{hi} monocytes (mean percentage +/- SD). **(j)** IFNγ production by CNS-isolated CD4 T cells after incubation with brefeldin A. Numbers on the representative contour plots show the mean percentage +/- SD of IFNγ^{+} out of CD4^{+} T cells. Graph shows absolute numbers (mean +/- SEM). N = 4-8 mice / group. **(c, j)** Two experiments pooled. **(d)** Three experiments pooled. **(f, h, i)** One experiment representative of 3 independent experiments. **(g)** Representative field of view taken from a brain per condition. See also Figure S1.

Figure 2. CD8 T cell responses against GRA6-OVA antigen are comparable whether or not bradyzoites express the antigen

(a) Schematics of the antigenic constructs introduced in GFP^+ Prugnaud strain (*Tg.*GFP). GRA6-OVA is driven either by the GRA6 promoter, active at the tachyzoite and bradyzoite stages, or by the tachyzoite-restricted SAG1 promoter. **(b)** Immunofluorescence staining of *ex vivo*-isolated cysts from CBA brains. Green: intrinsic parasite fluorescence and lectin-stained cyst wall. Red: GRA6-OVA detected with anti-SIINFEKL antibody. Blue: GRA2. Scale bar 10 µm. Right panel: quantification of SIINFEKL fluorescence within cyst. Each dot represents one cyst. **(c)** MHC I K^b presentation of GRA6-OVA-derived SIINFEKL peptide by MutuDC infected with the indicated parasite lines, assessed by absorbance measurements following incubation with LacZ-inducible OVA-specific B3Z CD8 T cell hybridomas. **(d)** Schematics of experimental infections in C57BL/6 mice infected i.p. with either of the 3 parasite strains. Evaluation of CD8 T cell responses 2 months post-infection. **(e-j)** IFNγ-producing CD8 T cells from spleen **(e, f, g)** or brain **(h, i, j)** following *in vitro* restimulation with OVA-derived SIINFEKL peptide **(f, i)** and Tgd057-derived SVLAFRRL peptide **(g, j)**. **(e, h) N**umbers on the representative contour plots show the mean percentage +/- SD of $IFN\gamma^+$ cells out of $CD8^+$ T cells**. (f, g, i, j)** Absolute numbers (mean +/- SEM) of $IFN\gamma^+$ $CD8^+$ T cells. N = 5 mice / group. Representative of two independent experiments. See also Figure S2.

Figure 3. Tachyzoite-restricted GRA6-OVA antigen confers sustained parasite control and protection against *T. gondii* encephalitis

(a) Schematics of experimental infections in C57BL/6 mice infected i.p. with either of the 3 parasite strains. Analyses of brain parasite load and immune infiltrates 2 months post-infection. **(b)** Brain cysts enumerated microscopically in infected C57BL/6 mice (mean +/- SEM). **(c, d)** Parasite burden measured by qPCR on genomic DNA from infected C57BL/6 **(c)** or CBA **(d)** brains (mean +/- SEM). **(e, f)** Analysis of inflammatory $CD45^{hi}$ $CD11b^+$ myeloid cells and resident

CD45^{int} CD11b^{+} ('microglia') cells. Numbers on the representative contour plots show the mean percentage +/- SEM of each subset out of single live Ly6G^{-} NK1.1^{-} cells. Graphs show the number of CD45^{int} CD11b^{+} microglia (mean +/- SEM) **(e)** or the ratio of CD45^{hi} over CD45^{int} cells (mean +/- SEM) **(f)**. **(g, h)** Expression level of MHC II **(g)** and CD86 **(h)** on the surface of microglia. Numbers on the representative histograms show the geomean +/- SD. Graphs display the fold-increase of each marker with respect to microglia from uninfected mice (mean +/- SEM). **(i)** Analysis of Ly6C^{hi} inflammatory monocytes. Numbers on the representative contour plots show the mean percentage +/- SD of Ly6C^{hi} cells out of single live Ly6G^{-} NK1.1^{-} CD45^{hi} CD11b^{+} cells. Graph shows absolute numbers (mean +/- SEM). **(j)** Expression level of CD86 on the surface of Ly6C^{hi} monocytes. Numbers on the representative histograms show the geomean +/- SD. Graph displays the fold-increase over uninfected (mean +/- SEM). **(k)** Proportion of MHC II^{+} cells (DC) among Ly6C^{hi} monocytes. Numbers on the representative histograms and the graph show mean percentages +/- SD. **(l)** IFNγ production by CNS-infiltrating CD4 T cells after incubation with brefeldin A. Numbers on the representative contour plots show the mean percentage of IFNγ^{+} out of CD4^{+} T cells +/- SD. Graph shows absolute numbers (mean +/- SEM). For all panels, N = 9 mice / group with 2 experiments pooled, except for **(l)** where N = 5 mice / group from one experiment.

Figure 4. Defective control of vacOVA-expressing *T. gondii* is not due to improper mobilization and effector differentiation of CD8 T cells in CNS

(a) Schematics of experimental infections in C57BL/6 mice infected i.p. with either of the 3 parasite strains. Evaluation of CD8 T cell responses in spleen and brain 3 weeks post-infection. **(b, d)** K^{b}-SIINFEKL dextramer labeling of spleen **(b)** and brain-infiltrating **(d)** CD8 T cells. Numbers on the representative contour plots show the mean percentage of dextramer^{+} out of CD8^{+} T cells +/- SD. Graph shows mean +/- SEM of absolute numbers. **(c, e)** Absolute numbers of IFNγ-producing CD8 T cells from spleen **(c)** and brain **(e)** following *in vitro* restimulation with OVA-derived SIINFEKL peptide (mean +/- SEM). **(f)** Analysis of triple-producing IFNγ^{+} TNF^{+} granzyme B^{+} brain CD8 T cells after restimulation with SIINFEKL peptide. Numbers on the

representative contour plots show mean percentage of TNF^+ granzyme B^+ out of $IFN\gamma^+$ CD8 T cells +/- SD. Graph shows absolute numbers of triple-producing CD8 T cells (mean +/- SEM). N=5 mice/ group. **(b, c, d, e)** Representative of 4 independent experiments. **(f)** Representative of 3 independent experiments.

Figure 5. Poorer K^b-SIINFEKL presentation by neurons infected with *T. gondii* expressing vacOVA compared to neurons infected with *T. gondii* expressing GRA6-OVA

(a) Timeline of antigen presentation assay with *Tg*-infected primary neuronal cultures. AraC was added to inhibit growth of glial cells. **(b, c)** Tropism and infection rate of the two $Tomato^+$ parasites following co-staining with MAP2 (green) and GFAP (blue). Pictures represent maximum intensity projections. Out of 24 fields, no vacuole was detected in a glial cell. Scale bar 10 µm. **(d)** K^b–SIINFEKL presentation by primary neurons infected for 24 h with the indicated tachyzoites, assessed by absorbance measurements following incubation with SIINFEKL-specific LacZ-inducible B3Z CD8 T cell hybridomas. **(b, c, d)** Representative of 2 independent experiments. See also Figure S3.

Figure 6. MHC I presentation by CNS neurons is required for efficient brain control of *T. gondii* at chronic phase

(a) Schematic representation of the L^dLox DNA cassette introduced in C57BL/6 fertilized eggs to generate the B6.L^dLox mice. The cassette is a 12-kb genomic sequence comprising the L^d gene modified with 2 LoxP sites flanking exons 1 to 3 (domains L, N and C1 according to nomenclature from (Evans et al., 1982)) and the endogenous 5' and 3' UTR regulatory sequences from BALB/c. **(b, c)** Flow cytometry labeling of H-2 K^b **(b)** and H-2 L^d **(c)** on the surface of $CD19^-$ $CD3^+$ T cells, $CD3^-$ $CD19^+$ B cells and $CD3^-$ $CD19^-$ $CD11c^+$ DC in the spleen of the indicated mouse strains. Numbers on the histograms show the geomean +/- SD. **(b, c)** Representative of two independent experiments. N=2-4 mice / group. **(d)** Schematics of experimental infections in C57BL/6, B6.L^dLox and congenic B6.H-2^d mice infected i.p. with

Tg.pTUB/vacOVA, which naturally expresses GRA6. Evaluation of CD8 T cell responses and parasite load 3 weeks later. **(e, f)** Absolute numbers of IFNγ-producing CD8 T cells isolated from spleen **(e)** and brain **(f)**, following *in vitro* restimulation with L^d-restricted GRA6-derived HF10 peptide (mean +/- SEM). **(g)** Number of brain cysts in mice of the indicated genotypes (mean +/- SEM). **(e-g)** Two experiments pooled with N=3-4 mice / group. **(h)** Schematics of the breeding strategy and outcome in terms of MHC I molecules expressed by neurons *vs.* non-neuronal cells in Cre^- and Cre^+ mice. **(i)** Schematics of experimental infections in C57BL/6, B6.L^dLox.Cre^+ or Cre^- infected *per os* with 15 cysts of the 76K strain. Evaluation of CD8 T cell responses and brain parasite load 3 weeks later. **(j)** Number of brain cysts enumerated microscopically. **(k)** Brain parasite burden measured by qPCR on genomic DNA. **(l)** Absolute number of total CD8 T cells isolated from infected brains. **(m)** Absolute numbers of brain-isolated IFNγ-producing CD8 T cells, following *in vitro* restimulation with L^d-restricted GRA6-derived HF10 peptide. **(j-m)** Graphs show the mean +/- SEM. N=5-6 mice / group. Representative of 2 independent experiments. See also Figure S4, S5 and S6.

556 **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
LEAF™ Purified anti-mouse CD16/32 antibody	BioLegend	Cat# 101321, RRID:AB_1877064
PE Rat Anti-Mouse CD8a	Thermo Fisher Scientific	Clone 53-6.7; Cat# 12-0081-83; RRID:AB_465531
BV421 Rat Anti-Mouse CD8a	BD Biosciences	Clone 53-6.7; Cat# 563898; RRID:AB_2738474
BV510 Rat Anti-Mouse CD4	BD Biosciences	Clone RM4-5; Cat# 563106; RRID:AB_2687550
PE-Cy™7 Rat Anti-Mouse CD4	BD Biosciences	Clone RM4-5 ; Cat# 552775; RRID:AB_394461
APC Rat Anti-Mouse IFN-γ	BD Biosciences	Clone XMG1.2; Cat# 554413; RRID:AB_398551
Alexa Fluor® 700 Rat anti-Mouse TNF	BD Biosciences	Clone MP6-XT22; Cat # 558000; RRID:AB_396980
PE Rat anti-mouse Granzyme B Monoclonal Antibody, eBioscience™	Thermo Fisher Scientific	Clone NGZB; Cat # 12-8898-82; RRID:AB_10870787
BV421 Hamster Anti-Mouse CD3e	BD Biosciences	Clone 145-2C11; Cat # 562600; RRID:AB_11153670
PE-Cy™7 Rat Anti-Mouse CD19	BD Biosciences	Clone 1D3; Cat # 552854; RRID:AB_394495
PE Hamster Anti-Mouse CD11c	BD Biosciences	Clone HL3; Cat # 557401; RRID:AB_396684
PE-CF594 Rat Anti-CD11b	BD Biosciences	Clone M1/70; Cat # 562287; RRID:AB_11154216
PerCP-Cy5.5 mouse anti-mouse H-2K^{b} Antibody	Biolegend	Clone AF6-88.5; Cat # 116516; RRID:AB_1967133
Alexa Fluor® 700 Rat Anti-Mouse CD4	BD Biosciences	Clone RM4-5; Cat # 557956; RRID:AB_396956
Brilliant Violet 510™ Rat anti-mouse Ly-6G	BioLegend	clone 1A8; Cat # 127633; RRID:AB_2562937
PerCP-Cy™5.5 Rat Anti-Mouse CD45	BD Biosciences	Clone 30-F11; Cat # 550994; RRID:AB_394003
PE Mouse Anti-Mouse NK-1.1	BD Biosciences	Clone PK136; Cat# 557391; RRID:AB_396674
Alexa Fluor® 700 rat anti-mouse CCR2	R & D Systems	Clone # 475301; Cat # FAB5538N; RRID:AB_2725739
APC Rat anti-Mouse CD86	BD Biosciences	clone GL1; Cat # 558703; RRID:AB_2075114
Brilliant Violet 711™ Rat anti-mouse Ly-6C	BioLegend	clone HK1.4; Cat # 128037; RRID:AB_2562630
PE Rat Anti-CD11b	BD Biosciences	Clone M1/70; Cat # 553311; RRID: AB_394775
Alexa Fluor 700 rat anti-mouse CD86	BD Biosciences	Clone GL1; Cat # 560581; RRID:AB_1727517
FITC Rat Anti-Mouse I-A/I-E	BD Biosciences	Clone 2G9; Cat # 553623; RRID:AB_394958

FITC Hamster anti-mouse CD3	BD Biosciences	Clone 145-2C11; Cat # 553062; RRID:AB_394595
Monoclonal Anti-MAP2 (2a+2b) antibody produced in mouse	Sigma-Aldrich	clone AP-20; Cat # M1406; RRID:AB_477171
Anti-Glial Fibrillary Acidic Protein (GFAP) antibody	Millipore	Cat # AB5804; RRID:AB_2109645
Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488	Invitrogen	Cat # A-11001; RRID:AB_2534069
Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 647	Invitrogen	Cat # A-21244; RRID:AB_2535812
Goat anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 594	Invitrogen	Cat # A-11032; RRID:AB_2534091
F(ab')2-Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488	Invitrogen	Cat # A-11070; RRID:AB_2534114
Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 555	Invitrogen	Cat # A21429; RRID:AB_2535850
Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 647	Invitrogen	Cat # A-21235; RRID: AB_2535804
Anti-Rabbit IgG (H+L), HRP Conjugate antibody	Promega	Cat # W4011; RRID:AB_430833
Anti-Mouse IgG (H+L) Antibody, HRP Conjugated	Promega	Cat # W4021; RRID:AB_430834
Rabbit anti-HPGSVNEFDF	(Buaillon et al., 2017)	N/A
Rabbit anti-SIINFEKL	Biotem, this study	N/A
Mouse anti-GRA 1	Biotem; M.-F. Cesbron-Delauw	clone TG17.43
Mouse anti-GRA2	Biotem; M.-F. Cesbron-Delauw	clone Tg17-179
H2-K^b-SIINFEKL Dextramer PE	Immudex	Cat # JD2163
Rabbit anti-TgProfilin	D. Soldati-Favre	PRF556
Rabbit anti-chicken OVA	Sigma	Cat # C6534; RRID: AB_258953
Rabbit anti-Iba1	Wako	Cat # 019-19741; RRID: AB_839504
Rabbit anti-MAP2	Millipore	Cat# AB5622; RRID: AB_91939
anti-H-$2L^d$ AF647	Biotem, (Ozato et al., 1980)	clone 30-5-7
Bacterial and Virus Strains		
Biological Samples		
Chemicals, Peptides, and Recombinant Proteins		
HPGSVNEFDF (HF10)	Genecust	N/A
SIINFEKL	Genecust	N/A
SVLAFRRL	Genecust	N/A
Mouse IFN-γ premium grade	Miltenyi Biotec	Cat # 130-105-774
Mycophenolic acid	Sigma-Aldrich	Cat # M5255
Xanthine	Sigma-Aldrich	Cat # X-2502
DNAse I from bovine pancreas	Sigma-Aldrich	Cat # DN25

Collagenase D from *Clostridium Histolyticum*	Roche	Cat # 11088882001
Rhodamine labeled Dolichos Biflorus Agglutinin (DBA)	Vector Laboratories	Cat # RL-1032; RRID: AB_2336396
eBioscience™ Fixable Viability Dye eFluor™ 450	Invitrogen	Cat # 65-0863-14
eBioscience™ Fixable Viability Dye eFluor™ 660	Invitrogen	Cat # 65-0864-14
LIVE/DEAD™ Fixable Green Dead Cell Stain Kit, for 488 nm excitation	Invitrogen	Cat # L34970
Triton X-100	Sigma-Aldrich	Cat # X100
Tween®20	Sigma-Aldrich	Cat # P1379
ProLong Diamond Anti-Fade Mounting medium with DAPI	Invitrogen	Cat # P36962
Paraformaldehyde 20 % aqueous solution	Electron Microscopy Sciences	Cat # 15713
Apicidin	Sigma-Aldrich	Cat # A8851
Laemmli Sample Buffer	BIO-RAD	Cat #1610737
Percoll	GE Healthcare	Cat # 17-0891-01
eBioscience Brefeldin A solution	Thermo Fisher Scientific	Cat # 00-4506-51
eBioscience Permeabilization Buffer (10X)	Thermo Fisher Scientific	Cat # 00-8333-56
Poly-D-lysine	Merck Millipore	Cat # A-003-E
UltraPure™ DNase/RNase-Free Distilled Water	Invitrogen	Cat # 10977035
Laminin Mouse Protein, Natural	Invitrogen	Cat # 23017-015
Papain	Worthington Biochemical Corporation	Cat # LK003176
Bovine Serum Albumin	Dutscher	Cat # SH30574.02
Trypsin Inhibitor from chicken egg white	Roche	Cat # 10109878001
B-27 supplement	Gibco	Cat # 17504044
GlutaMAX Supplement	Gibco	Cat # 35050061
Cytarabine Hydrochloride	Sigma-Aldrich	Cat # C6645
Normal Goat Serum	Vector Laboratories	Cat # S-1000
chlorophenol red-β-D-galactopyranoside CPRG	Roche	Cat # 10884308001
Glutaraldehyde 8% aqueous solution	Electron Microscopy Science	Cat # 16019
X-gal	Sigma-Aldrich	Cat # B4252
Potassium Ferrocyanide	Sigma-Aldrich	Cat # 60279
Potassium Ferricyanide	Sigma-Aldrich	Cat # 60299
Magnesium Chloride Hexahydrate	Sigma-Aldrich	Cat # M2670
Tetrodotoxin	Sigma-Aldrich	Cat # T8024
TBS	Euromedex	Cat # ET220
DAPI	Sigma-Aldrich	Cat # D9542
Fluoromount medium	Electron Microscopy Sciences	Cat # 17984-25
Critical Commercial Assays		

DNEasy Blood and Tissue Kit	Qiagen	Cat # 69504
Deposited Data		
Experimental Models: Cell Lines		
MutuDC	(Fuertes Marraco et al., 2012), H. Acha-Orbea	N/A
Human Foreskin Fibroblasts (HFF)	ATCC	Cat# SCRC-1041
SIINFEKL-specific LacZ-inducible CD8 T cell reporter hybridomas (B3Z)	(Karttunen et al., 1992), N. Shastri	N/A
Experimental Models: Organisms/Strains		
Mouse: CBA: CBA/JRj	Janvier	N/A
Mouse: B6 or C57BL/6: C57BL/6J	Janvier	N/A
Mouse: B6.H-2^d: B6.C-$H2^d$/bByJ	Jax	Cat # 000359
Mouse: B6.CamKIIα-iCre	(Casanova et al., 2001), G. Schutz	N/A
Mouse: B6.L^dLox:	This study	N/A
T. gondii: 76K	(Bonnart et al., 2017); D. Buzoni-Gatel	N/A
T. gondii: *Tg*.Tomato: Pru.Δ*hxgprt*.*tdTOMATO*$^{\text{prom TUB}}$	(Schaeffer et al., 2009)	N/A
T. gondii: *Tg*.pTUB/vacOVA: Pru.Δ*hxgprt*.*tdTOMATO*$^{\text{prom TUB}}$.*SAG1ΔGPI-OVA*$_{[140\text{-}386]}^{\text{prom TUB/3'utr DHFR}}$ *+BLE*	(Schaeffer et al., 2009)	N/A
T. gondii: *Tg*.pGRA6/GRA6-OVA: Pru.Δ*hxgprt*.*tdTOMATO*$^{\text{prom TUB}}$.*GRA6*$_{II}$*-LEQLE-SIINFEKL*$^{\text{prom GRA6/3'utr GRA2}}$ *+HXGPRT*	This study	N/A
T. gondii: *Tg*.GFP: Pru.Δ*hxgprt*.*GFP*$^{\text{prom GRA1}}$.*click beetle LUC*$^{\text{prom DHFR}}$	(Kim et al., 2007)	N/A
T. gondii: *Tg*.pGRA6/GRA6-OVA: Pru.Δ*hxgprt*.*GFP*$^{\text{prom GRA1}}$.*click beetle LUC*$^{\text{prom DHFR}}$.*GRA6*$_{II}$*-LEQLE-SIINFEKL*$^{\text{prom GRA6/3'utr GRA2}}$ *+HXGPRT*	This study	N/A
T. gondii: *Tg*.pSAG1/GRA6-OVA: Pru.Δ*hxgprt*.*GFP*$^{\text{prom GRA1}}$.*click beetle LUC*$^{\text{prom DHFR}}$.*GRA6*$_{II}$*-LEQLE-SIINFEKL*$^{\text{prom SAG1/3'utr GRA2}}$ *+HXGPRT*	This study	N/A
Oligonucleotides		
TOX9: 5'-AGGAGAGATATCAGGACTGTAG	(Feliu et al., 2013)	N/A
TOX11: 5'-GCGTCGTCTCGTCTAGATCG	(Feliu et al., 2013)	N/A
pri58-F: 5'-TTCCGAGCAGGTGACCTGGGTC	This study	N/A

pri92-R: 5'-CGTACGGGTACCATGGTTACAGTTTTTCAAAGTTGATTATACTCTCAAGCTGCTCAAGAAAATCAAACTCATTCACACTTCCCGGGT	This study	N/A
pri28F : 5'-CTAGATACCGTTCGTATAATGTATGCTATACGAAGTTATACTAGTGCTAGCATAACTTCGTATAATGTATGCTATACGAACGGTAT	This study	N/A
pri29R : 5'-CTAGATACCGTTCGTATAGCATACATTATACGAAGTTATGCTAGCACTAGTATAACTTCGTATAGCATACATTATACGAACGGTAT	This study	N/A
Recombinant DNA		
pL^d4	(Evans et al., 1982), T. Hansen	internal ID: NBpla93
pL^d4Lox	This study	internal ID: NBpla100
pGRA6/GRA6-OVA	This study	internal ID: NBpla119
pSAG1/GRA6-OVA	This study	internal ID NBpla190
Software and Algorithms		
ImageJ	NIH	N/A
FlowJo	TreeStar	N/A
Prism	GraphPad	N/A

STAR Methods

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Nicolas Blanchard (nicolas.blanchard@inserm.fr)

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Human cell lines

Human Foreskin Fibroblasts (HFF) were purchased from ATCC (see Key Resources Table). They were maintained in DMEM supplemented with 10 % FCS (Gibco). Gender is unknown.

Mouse cell lines and primary cells

MutuDC, a C57BL/6-derived dendritic cell line, were obtained from H. Acha-Orbea (see Key Resource Table) and grown using the recommended protocol, as in (Fuertes Marraco et al., 2012). Bone marrow-derived DC from F1 C57BL/6 X B6.H-2^{d} (H-2^{bxd}) mice were generated as in (Buaillon et al., 2017).

Toxoplasma gondii

For all experiments, type II 76K or Prugnaud (Pru) derivatives (see Key Resource Table for details) were used. Pru tachyzoites were maintained *in vitro* by serial passages on confluent monolayers of HFF using DMEM supplemented with 1 % FCS (Gibco). 76K parasites were passaged *in vivo* in CBA mice by *per os* inoculation of 100 cysts every 2-month. For intra-peritoneal infections, infected HFF were scraped, tachyzoites were released through a 23G needle, filtered through a 3 µm polycarbonate hydrophilic filter (it4ip S.A.) and 2-5x10^2 tachyzoites were injected in 200 µl PBS. For *per os* infections, 200 µl of brain homogenate containing 15 cysts was administered by oral gavage.

Mice

Animal care and use protocols were carried out under the control of the National Veterinary Services and in accordance with the European regulations (EEC Council Directive, 2010/63/EU, September 2010). Protocols inducing pain (CE no. 2015-02) were approved by the local Ethical

Committee for Animal Experimentation registered by the 'Comité National de Réflexion Ethique sur l'Expérimentation Animale' under no. CEEA122. CBA/JRj and C57BL/6J (B6) mice were purchased from Janvier (France). B6.C-H2^{d}/bByJ, abbreviated as B6.H-2^{d}, were purchased from Jackson Laboratories (Bar Harbor, ME, USA). F1 C57BL/6 X B6.H-2^{d} (H-2^{bxd}) were bred for this study. B6.CamKIIα-iCre were a gift from G. Schutz (Casanova et al., 2001). B6.L^{d}Lox were generated by additive transgenesis following microinjection of a linearized DNA cassette containing a floxed H-2L^{d} allele into the pronucleus of C57BL/6J fertilized eggs. The floxed L^{d} gene with two LoxP sites flanking exons 1 to 3 was obtained after modification of the pL^{d}4 plasmid that harbors a 12-kb BALB/c-derived genomic sequence (Evans et al., 1982). More details on the pL^{d}4Lox plasmid construction are shown below. All mice were housed and bred under specific pathogen-free conditions at the 'Centre Régional d'Exploration Fonctionnelle et de Ressources Expérimentales' (CREFRE-Inserm UMS006). Age of mice used in experiments was 8-20 weeks. Mice used in experiments were males. Mice in B6.L^{d}Lox.CamK-Cre$^{+/-}$ experiments were littermates. Number of mice and experimental replicates are indicated in the respective figure legends.

METHOD DETAILS

Generation of transgenic parasites

Hxgprt-deficient GFP^{+} (Kim et al., 2007) and tdTomato^{+} Pru (Schaeffer et al., 2009) were used as parental strains. Tachyzoites were transfected with plasmids encoding the GRA6$_{II}$ open-reading frame in frame with nucleotides encoding LEQLE-SIINFEKL, yielding the GRA6-OVA antigenic construct. GRA6-OVA was flanked by *gra2* 3' UTR and by either the endogenous *gra6* promoter and 5' UTR (pGRA6/GRA6-OVA) or the by the *sag1* promoter and 5'UTR (pSAG1/GRA6-OVA). Plasmids were generated by a combination of DNA fragment synthesis (GeneArt, Thermo Fisher) and standard cloning procedures and verified by sequencing. Parasite transfections were performed as previously described (Feliu et al., 2013). In brief, 2x10^7 freshly egressed tachyzoites were electroporated with 50 μg of NotI (New England Biolabs)-linearized plasmid DNA. After selection in culture medium supplemented with mycophenolic acid (Sigma, 25

611 µg/ml) and xanthine (Sigma, 50 µg/ml), resistant tachyzoites were cloned by limiting dilution in
612 flat-bottom 96-well plates and presence of the transgene was verified by PCR and sequencing.

613 **Bradyzoite differentiation and Western blot**

614 For *in vitro* bradyzoite differentiation assays, HFF were seeded in 6-W plates and infected with
615 10^6 tachyzoites. After 24 h, the medium was replaced and supplemented with 40 nM of the
616 histone deacetylase inhibitor apicidin (Sigma-Aldrich) in order to promote bradyzoite
617 differentiation(Bougdour et al., 2009; Boyle et al., 2006). After 24 h for the untreated or 72 h
618 for the apicidin-treated, parasites were released with a 23-G needle, lyzed in 1x Laemmli buffer
619 (Bio-Rad) containing 10 % 2-mercaptoethanol (Bio-Rad) and heated for 5 min at 70°C. Total cell
620 lysates were forced through a 29-G needle, separated by electrophoresis on 15 %
621 polyacrylamide gels and transferred to nitrocellulose membranes. Immunologic detection was
622 performed using purified rabbit anti-SIINFEKL antisera (custom-made, Biotem, Grenoble) and
623 mouse anti-GRA1 (Biotem) followed by horseradish peroxidase-conjugated antibodies
624 (Promega). Peroxidase activity was visualized by chemiluminescence and quantified using a
625 ChemiDoc XRS+ system (Bio-Rad).

626 **Isolation of spleen and brain leukocytes**

627 Spleens and brains were dissociated in complete RPMI (Gibco) supplemented with 10 % vol/vol
628 FCS (Gibco). Splenocytes were mashed through a 100 µm cell strainer (Falcon). Brains were
629 homogenized using a Potter, minced and digested for 45 min in RPMI containing 1 mg/ml
630 collagenase (Roche) and 0.1 mg/ml DNAse (Sigma-Aldrich). Samples were then centrifuged at
631 600 g and suspended in 60 % (vol/vol) Percoll (GE Healthcare). A 30 % (vol/vol) Percoll solution
632 was overlaid and the tubes were centrifuged at 1000 g for 20 min. Brain leukocytes were
633 recovered from the interface. In both cases, erythrocytes were lyzed using ACK buffer (100 µM
634 EDTA, 160 mM NH_4Cl and 10 mM $NaHCO_3$).

635 ***Ex vivo* T cell stimulation**

636 One-fifth of Percoll-isolated brain leukocytes or 10^6 splenocytes were incubated for 4 h 15 min
637 at 37°C in the presence of brefeldin A (eBioscience) with 10^5 bone marrow-derived DC from F1

C57BL/6 X B6.H-2^{d} (H-2^{bxd}) mice or with C57BL/6-derived MutuDC (Fuertes Marraco et al., 2012), plus 200 nM of the following peptides as indicated in the legends: GRA6-derived HPGSVNEFDF (HF10) presented by H-2L^{d}, OVA-derived SIINFEKL presented by H-2K^{b} and Tgd057-derived SVLAFRRL presented by H-2K^{b}.

Flow cytometry

Following Fc receptor saturation (Biolegend) and dead cell detection with AF488 Live Dead/Cell marker (Invitrogen) in PBS, cell suspensions were surface labelled with CD8α BV421 (53-6.7, 1/300, BD Pharmingen) or CD8α PE (53-6.7, 1/300, eBioscience), CD4 BV510 (RM4-5, 1/200, BD Horizon) or CD4 Pe-Cy7 (RM4-5, 1/300, BD Pharmingen). Intracellular IFNγ (IFNγ-APC or AF700, XMG1.2 1/300, BD Pharmingen), TNFα (TNFα AF700, MP6-XT22, 1/300, BD Pharmingen), Granzyme B (Granzyme B PE, NGZB, 1/200, eBioscience) were detected after fixation in 4 % paraformaldehyde solution (PFA, Electron Microscopy Sciences) and permeabilization with the Permeabilization Buffer kit (eBioscience).

For *ex vivo* MHC I labeling, 10^6 splenocytes were stained with FcR block and AF488 Live/Dead cell marker in PBS. They were labelled with CD3 BV421 (145-2C1, 1/300, BD Horizon) or CD3 FITC (145-2C1, 1/300, BD Pharmingen), CD19 Pe-Cy7 (1D3,1/400, BD Pharmingen), CD11c PE (N418, 1/300, eBioscience), CD11b PE-CF594 (M1/70, 1/3000, BD Horizon) or CD11b PE (M1/70, 1/400, BD Pharmingen), anti-H-2L^{d} AF647 (30-5-7, 1/100, Biotem) or anti-H-2K^{b} PerCP-Cy5.5 (AF6-88.5, 1/300, Biolegend). Samples were fixed using 4% PFA.

For *ex vivo* K^{b}-SIINFEKL dextramer analysis, splenocytes and brain leukocytes were incubated 1 h at 37 °C with a solution of dextramer H-2 K^{b}-SL8 PE (1/50, Immudex). Cells were stained with FcR block and eFluor 660 Fixable Viability Dye (1/1000, eBioscience) in PBS and then labelled with CD8α BV421 (53-6.7, 1/300, BD Horizon) and CD4 AF700 (RM4-5, 1/200, BD Pharmingen) or CD4 BV510 (RM4-5, 1/200, BD Horizon).

To analyze the phenotype and activation of CNS-isolated myeloid cells, brain leukocytes were stained with FcR block and eFluor 450 Fixable Viability Dye (1/1000, eBioscience) in PBS and then labelled using the following antibodies: Ly6G BV510 (1/200, 1A8, Biolegend), CD45 PerCP-

Cy5.5 (30-f 11, 1/300, BD Pharmingen), CD11b PE-CF594 (M1/70, 1/3000, BD Horizon), NK1.1 PE (PK 136, 1/400, BD), CCR2 AF700 (FAB5538N, 1/200, R&D Systems), CD86 APC (GL1,1/300, BD Pharmingen) or CD86 Alexa Fluor 700 (GL1, 1/500, BD Pharmingen), Ly6C BV711 (HK1.4, 1/1800, Biolegend), MHC II I-A/I-E FITC (2G9, 1/300, BD Pharmingen). In all cases, samples were ultimately fixed in 4 % PFA before acquisition on a BD Fortessa and analyzed using FlowJo (Tree Star).

Parasite load analysis

For cyst enumeration, 5 % of total brain homogenate was labeled with rhodamine or fluorescein-conjugated *Dolichos Biflorus* Agglutinin (Vector Laboratories). Cysts were counted using an inverted fluorescence microscope. Quantification of parasite DNA by qPCR was performed on genomic DNA extracted from 5 % of each brain homogenate, 10^6 splenocytes or 5x10^5 peritoneal exudate cells using the DNEasy Blood & Tissue Kit (Qiagen). As described earlier (Feliu et al., 2013), a 529-bp repeat element in the *T. gondii* genome was amplified using the TOX9 and TOX11 primers (sequences shown in Key Resource Table). The number of parasite genome per µg of tissue DNA was estimated by comparison with a standard curve, established with a known number of Pru tachyzoites.

IF labeling of *ex vivo* cysts

Five percent of the brain homogenate was stained with rhodamine-conjugated DBA lectin, fixed in 4% PFA for 10 min at room temperature (RT) and permeabilized in PBS - 0.2% Triton™ X100 (Sigma-Aldrich). Samples were then incubated with a custom-made rabbit anti-SIINFEKL (1/300, Biotem) or anti-OVA (1/500, Sigma) and a mouse anti-GRA2 (1/3000, Biotem) diluted in PBS BSA 3 % (Dutscher), followed by incubation with AF555-coupled anti-rabbit Immunoglobulin G (IgG) or AF488-coupled anti-rabbit (1/500) and AF647-coupled anti-mouse IgG (1/500, Life Technologies, Thermo Fisher) diluted in PBS-BSA 3 %. Samples were mounted using ProLong™ Diamond Anti-Fade containing DAPI (Life Technologies, Thermo Fisher scientific) and imaged using a Zeiss LSM710 confocal microscope. Quantifications of the GRA6-OVA signal were performed using ImageJ software (NIH). Briefly, a filled mask encompassing the entire area of

692 the cyst was created based on the DBA lectin staining and the parasite fluorescence. The mean
693 intensity of the GRA6-OVA signal of masked pixels was measured and averaged from 3
694 equatorial planes for every individual cyst.

695 **IF labeling of HFF**

696 HFF were infected with Tg.pGRA6/GRA6-OVA or Tg.pTUB/vacOVA parasites during 24 h. After 2
697 washes in PBS, cells were fixed in PFA 4% for 20 min at RT and quenched in PBS glycine 100mM
698 (Sigma) for 10 min at RT. Cells were then washed in PBS and incubated with primary polyclonal
699 rabbit OVA (1/500, Sigma) or rabbit anti-SIINFEKL (1/300, Biotem) in PBS-BSA 0,2%-saponin 0,05
700 %. After washing in the same buffer, cells were incubated with AF488-coupled anti-rabbit IgG
701 (1/500, Life Technologies). Coverslips were mounted using ProLong Diamond™ Anti-Fade
702 containing DAPI (Life Technologies, Thermo Fisher scientific). Images were acquired with a 63X
703 objective on a Zeiss LSM710 confocal microscope.

704 **Primary hippocampal neuronal cultures**

705 Primary neuronal cultures were derived from C57BL/6 embryonic day 17 hippocampi. One day
706 before dissection, flat-bottom 24-well plates with glass coverslips and flat-bottom 96-well plates
707 were coated with Poly-D-lysine (Merck) dissolved in Ultra-Pure™ Distilled Water (Gibco) to the
708 final concentration of 38,5 µg/ml. Coated plates were stored overnight at 37°C. The day of the
709 dissection, plates were washed twice with Ultra-Pure™ Distilled Water (Gibco) and coated with
710 laminin (mouse, 1/500, Invitrogen) during 3 h at 37°C. After dissection, hippocampi were
711 digested 8 min at 37°C with Papain solution (Worthington Biochemical Corp.) at 1 U/ml final
712 activity. Digestion was stopped using a solution composed of 1.5 mg/ml BSA (Dutscher),
713 1.5 mg/ml Trypsin inhibitor from chicken egg white (Sigma-Aldrich) and 66.7 µg/ml DNAse
714 (Sigma-Aldrich) in PBS. Tissues were mechanically dissociated by trituration with a plastic
715 pipette, filtered through a 70 µm strainer (Falcon) and centrifuged at 210 g for 7 min. Cells were
716 suspended in Neurobasal®-A medium (Gibco) containing 2% B27® Supplement (vol/vol) (Gibco),
717 1% GlutaMAX™-I (vol/vol) (Gibco), 120 U/ml Penicillin, 120 µg/ml Streptomycin (Gibco) and
718 seeded at 2x10^5 cells per well for the 24-well plate and 4x10^4 cells per well for the 96-well

719 plate. Cells were then incubated at 37°C, 5% CO_2. At day 4 and 8, primary cultures were treated
720 with 5 µM of cytarabine hydrochloride (AraC) (Sigma-Aldrich) in order to inhibit growth of glial
721 cells. At day 11, 100 U/ml of mouse IFNγ (Miltenyi Biotec) was added. Twelve days after the
722 beginning of the culture, neurons were infected with *Tg*.pGRA6/GRA6-OVA or *Tg*.pTUB/vacOVA
723 strains. Respectively, 5x10^4 or a serial dilution of 5x10^4 to 2x10^3 tachyzoites were added in
724 each well of the 24-well or 96-well plate. To assess L^d expression, hippocampal cultures were
725 established with B6.L^dLox.Cre+/- pups at postnatal day 1 using a similar procedure as above,
726 with the following modifications: 1,5x10^5 cells were seeded per well in a 24 - well plate and
727 were not treated with AraC. At day 13, primary cultures were treated with mouse IFNγ
728 (0,5 µg/ml) and 1 µM Tetrodotoxin (TTX) (Sigma-Aldrich) as in (Chevalier et al., 2011).

729 **IF labeling of primary neuronal cultures**

730 Twenty-four hours after infection, cells were fixed with 4 % PFA for 20 min at RT. After 2 x 5
731 min washes with PBS, cells were permeabilized with PBS - 0,05 % Triton™ X100 (Sigma-Aldrich)
732 for 5 min at RT. Following 3 x 5 min washes in PBS, non-specific binding sites were blocked with
733 PBS - 5 % Normal Goat Serum (NGS) (Vector Laboratories) - 0,05 % Tween®20 (Sigma-Aldrich)
734 for 1 h at RT. Cells were incubated overnight at 4°C with primary monoclonal mouse anti-
735 microtubule-associated protein 2 (MAP2, AP-20, 1/500, Sigma-Aldrich) and polyclonal rabbit
736 anti-glial fibrillary acidic protein (GFAP, 1/500, Merck) diluted in PBS - 3 % NGS - 0,05 %
737 Tween®20. Cells were washed 1 x 5 min with PBS, 3 x 5 min with PBS - 0,05 % Tween®20 and 5
738 min with PBS. Cells were incubated for 2 h at RT in presence of secondary antibodies AF488-
739 coupled anti-mouse immunoglobulin G (IgG) and AF647-coupled anti-rabbit IgG (Life
740 Technologies, Thermo Fisher) diluted in PBS - 3 % NGS - 0,05 % Tween®20 (1/500) and protected
741 from light. Samples were mounted using ProLong™ Diamond Anti-Fade with DAPI (Life
742 Technologies, Thermo Fisher). Z-stacks were acquired with a 63X objective on a Zeiss LSM710
743 confocal microscope and analyzed using ImageJ software. Extracellular H-2 L^d was stained with
744 1,2 µg/ml of mouse anti L^d (clone 30-5-7, Biotem) diluted in PBS-3 % NGS for 30 min on ice
745 followed by two washes with cold PBS. Steps of intracellular staining were the same as
746 described above except for the antibodies used. Cells were stained with a polyclonal rabbit

anti-microtubule-associated protein 2 (MAP2, 1/1000, Merck) or with a polyclonal rabbit anti-glial fibrillary acidic protein (GFAP, 1/500, Merck), followed by both AF488-coupled anti-rabbit IgG (1/500, Life Technologies, Thermo Fisher) and AF594-coupled anti-mouse IgG (1/500, Life Technologies, Thermo Fisher). Quantification of L^d labeling was done with ImageJ. The intensity of L^d labeling was recorded on multiple sections after applying a mask corresponding to the $MAP2^+$ or $GFAP^+$ pixels.

IF labeling of brain cortical floating sections

After transcardial perfusion with NaCl 0,9 %, hemibrains were removed, fixed in 4 % PFA for 48 h at 4°C and washed in PBS for 5 min and 24 h at 4°C. Brains were transferred in PBS - 30 % sucrose for 48 h at 4°C, sectioned coronally at 25 µm-thickness and stored in PBS - 30 % ethylene glycol - 30 % glycerol at -20°C until processed further. For this, sections were washed 4 X 5 min in TBS (Euromedex), permeabilized with TBS - 0,1 % Triton™ X100 (Sigma-Aldrich) for 10 min at RT and rinsed once with TBS for 5 min. After antigen retrieval with TBS - 100 mM Tris - 12 mM EDTA - 0,05 % Tween®20 (Sigma-Aldrich) at pH 9 during 20 min at 100°C, brain sections were washed 3 X 5 min in TBS. Non-specific binding sites were blocked with TBS - 5 % Normal Goat Serum (NGS) (Vector Laboratories) - 5 % BSA (Dutscher) - 0,1 % Tween®20 for 1 h at RT. Floating sections were incubated overnight at 4°C with rabbit anti-Iba1 (1/1000, Wako) in TBS - 3 % NGS - 0,1 % Tween®20. Following several washes in TBS - 0,1 % Tween®20 and TBS, sections were incubated for 2 h at RT with secondary antibody AF647-coupled anti-rabbit IgG (Thermo Fisher) diluted in TBS - 3 % NGS - 0,1 % Tween®20 (1/500) and protected from light. Samples were washed alternatively in TBS - 0,1 % Tween®20 and TBS twice and incubated with 1 µg/ml of DAPI (Sigma-Aldrich) in TBS for 30 min at RT. Sections were mounted in Fluoromount medium (Electron Microscopy Sciences) after 2 washes in TBS. Images were acquired with 5 X and 20 X objectives on Apotome Zeiss microscope and analyzed using ImageJ software.

***In vitro* antigen presentation assays**

Antigen presentation measurements with MutuDC were performed as described in(Buaillon et al., 2017). In brief, 5x10^4 MutuDC were seeded into flat-bottom 96-well plates and infected for 24 h with serially diluted tachyzoites. The proportion of infected cells (i.e. GFP^+ or $Tomato^+$) was controlled by flow cytometry. Presentation of the SIINFEKL peptide by K^b was assessed following 16 h incubation at 37°C with 10^5 LacZ-inducible B3Z reporter hybridomas per well. Production of β-galactosidase by the hybridomas was quantified using the chromogenic substrate chlorophenol red-β-D-galactopyranoside (CPRG, Roche). Absorbance was read at 595 nm with a reference at 655 nm with a spectrophotometer (VersaMax, Molecular Devices).

For antigen presentation with primary neurons, 24 h after neuron infection, 10^5 B3Z reporter hybridomas were seeded per well of the 96-well plate and incubated for 16 h at 37°C. After fixation with 2 % PFA - 0,2 % glutaraldehyde (Electron Microscopy Sciences) for 20 min at RT and 2 x 5 min washes with PBS, cells were incubated with a solution containing 1 mg/ml 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-gal, Sigma-Aldrich), 5 mM potassium ferrocyanide (Sigma-Aldrich), 5 mM potassium ferricyanide (Sigma-Aldrich), 2 mM MgCl2 (Sigma-Aldrich) in PBS. X-gal-positive (blue) cells were counted microscopically with a 20X magnification. With neurons, the X-gal assay was preferred over the bulk CPRG read-out because of its higher sensitivity.

Plasmids

pGRA6/GRA6-OVA

The pGRA6/GRA6-OVA plasmid was constructed by In-fusion (Takara) cloning of a GRA6(II)-LEQLE-SIINFEKL insert (abbreviated as GRA6-OVA) into the 5' BstEII / 3' NcoI-linearized and gel purified pGRA.HPT.GRA6(II) vector, a *T. gondii* expression vector containing a HXGPRT resistance cassette (Feliu et al., 2013). The GRA6-OVA sequence was PCR-amplified from type II Pru genomic DNA using a forward (pri58-F) and a reverse primer (pri92-R) (sequences shown in Key Resource Table) in order to introduce the LEQLE-SIINFEKL coding sequence at the C-terminus of GRA6(II) and to add extremities annealing with the ends of the linearized vector for the fusion cloning. The resulting pGRA6/GRA6-OVA plasmid (internal ID NBpla119) contains the GRA6-

OVA coding sequence flanked by the endogenous GRA6(II) promoter/5'UTR and the 3'UTR from GRA2(I) as well as the HXGPRT resistance cassette.

pSAG1/GRA6-OVA

To obtain the pSAG1/GRA6-OVA plasmid, the pGRA6/GRA6-OVA plasmid was modified to replace the GRA6(II) promoter/5'UTR and GRA6-OVA coding sequence by a synthetic DNA fragment containing the SAG1 promoter/5'UTR and GRA6-OVA coding sequence using 5' HindIII/3' NcoI restriction cloning. The sequence of the introduced synthetic fragment is shown below, with HindIII/NcoI sites underlined and GRA6-OVA ORF in bold:

AAGCTTTTACATCCGTTGCCTTTTCCACGGTCCGTGATTTCATGTGCGTGCAGCTTCAAAGACTGGTCGTT
GCGACTAATAAGACTGCAGTGACAGGTCGAATGGTGGGCACCTTGCTGATGACTATCTACTGCAAAGTC
TGAGACAACGAACGAAACTTCCCACACGAGGCATTTGAAACTGACGGTGTCTAGGTAATATGCACTGCA
AGACACGGTACTGGGGCCTCGCTGAATTAGGGGCCGATCTCGTTGCCCTATCAGTGCTCACAGTGCCGC
AACGTAACACCAGGGCAGGTTCTTGACAGTGGCAACAATGTGCGACGGGCGTGTGAACGTTTCGTAGTC
ATAGCGCTAGCACGTACCTAGCCACATGGTCGTGAGGAGCTTTACCATGCGTCTAGAAGGTGGATGCGG
GACACGCCTTCCTGGCCTTTGGCTCCCGAGACGCGTGTTCTAACCACAAACCTTGAGACGCGTGTTCCAA
CCACGCACCCTGACACGCGTGTTCCAACCACGCACCCTGAGACGCGTGTTCTAACCACGCACCCTGAGAC
GCGTGTTCTAACCACGCACCCTGAGACGCGTGTTCTGCCGCACAATGTGCACCTGTAGGAAGCTGTAGTC
ACTGCTGATTCTCACTGTTCTCGGCAAGGGCCGACGACCGGAGTACAGTTTTTGTGGGCAGAGCCGTTGT
GCAGCTTTCCGTTCTTCTCGGTTGTGTCACATGTGTCATTGTCGTGTAAACACACGGTTGT**ATGGCACACG**
GTGGCATCTATCTGAGGCAGAAGCGTAACTTCTGTCCTTTAACTGTCTCCACAGTTGCTGTGGTCTTTGT
AGTCTTCATGGGTGTACTCGTCAATTCGTTGGGTGGAGTCGCTGTCGCAGCAGACAGCGGTGGTGTTA
GGCAGACCCCTTCGGAAACCGGTTCGAGCGGTGGACAGCAAGAAGCAGTGGGGACCACTGAAGACTA
TGTCAACTCTTCGGCGATGGGCGGTGGCCAAGGCGACTCGTTAGCTGAAGATGATACAACCTCCGATG
CGGCGGAGGGCGACGTTGACCCTTTTCCCGCGCTGGCGAATGAGGGGAAGTCGGAGGCGCGTGGCCC
GTCGCTCGAGGAAAGAATCGAAGAACAGGGCACAAGACGACGTTACTCCTCTGTTCAAGAACCACAA
GCGAAGGTGCCTAGCAAACGAACACAGAAACGCCACAGACTCATTGGTGCTGTGGTGTTGGCAGTATC
TGTGGCAATGCTTACCGCTTTCTTTCTTCGAAGGACTGGACGACGCTCTCCCCAAGAACCATCTGGGGG
TGGTGGTGGAAATGATGCAGGCAATAATGCTGGGAACGGTGGGAATGAAGGCAGAGGTGAAGGAG

GCGAGGATGACAGGCGCCCGTTGCACCCGGGAAGTGTGAATGAGTTTGATTTTCTTGAGCAGCTTGAG
AGTATAATCAACTTTGAAAAACTGTAACCATGG

The resulting pSAG1/GRA6-OVA plasmid (internal ID NBpla 190) contains the GRA6-OVA coding sequence flanked by the SAG1 promoter/5'UTR and the 3'UTR from GRA2(I) as well as a HXGPRT resistance cassette.

pL^{d}4Lox plasmid

The pL^{d}4 plasmid (internal ID NBpla93, kind gift of T. Hansen) contains 12-kb of genomic sequence of BALB/c H-2 L^d gene inserted into pBR327 backbone between EcoRI and HindIII (Evans et al., 1982).

A pair of reverse complement primers (pri28F and pri29R, see sequences in Key Resource Table) were annealed *in vitro* in order to create two distinct LoxP sites (to make sure that recombination is irreversible) flanked by cohesive ends that permit cloning into **XbaI** site. **SpeI** and **NheI** restriction sites, which are compatible for religation with **XbaI**, were included between the LoxP sites:

CTAG**ATACCG**TTCGTATAATGTATGCTATACGAAGTTAT**ACTAGT**GCTAGCATAACTTCGTATAATGTATG
CTATACGAACGGTAT

The XbaI-digested annealed fragment was cloned into XbaI-linearized pUC19 to obtain pUC19 | LoxP |SpeI |NheI | LoxP (internal ID NBpla95). A 1.6kb XbaI-excised fragment from pL^{d}4 containing the first 3 exons (L,N,C1 (Ozato et al., 1983)) was cloned into NheI-linearized pUC19 | LoxP |SpeI |NheI | LoxP to obtain pUC19 | LoxP | SpeI | L^d exons 1-3 | LoxP (internal ID NBpla99).

The LoxP | SpeI | L^d exons 1-3 | LoxP fragment was then excised with XbaI and cloned into XbaI-opened pL^{d}4 to obtain pL^{d}4Lox (internal ID Nbpla100). Clones were confirmed by restriction digest and sequencing.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analyses for all experiments were performed with Prism software v7 (GraphPad). In experiments comparing only two groups, non-parametric Mann-Whitney tests were used to compare the experimental group with the control group. For other experiments including 3 groups, non-parametric ANOVA tests (Kruskal-Wallis with Dunn's correction for multiple tests) were used. Individual P values are indicated on the figures.

References

Bernard-Valnet, R., Yshii, L., Queriault, C., Nguyen, X.H., Arthaud, S., Rodrigues, M., Canivet, A., Morel, A.L., Matthys, A., Bauer, J., *et al.* (2016). CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice. Proc Natl Acad Sci U S A *113*, 10956-10961.

Bhadra, R., Cobb, D.A., and Khan, I.A. (2013). Donor CD8+ T cells prevent Toxoplasma gondii de-encystation but fail to rescue the exhausted endogenous CD8+ T cell population. Infect Immun *81*, 3414-3425.

Biswas, A., Bruder, D., Wolf, S.A., Jeron, A., Mack, M., Heimesaat, M.M., and Dunay, I.R. (2015). Ly6C(high) monocytes control cerebral toxoplasmosis. J Immunol *194*, 3223-3235.

Biswas, A., French, T., Dusedau, H.P., Mueller, N., Riek-Burchardt, M., Dudeck, A., Bank, U., Schuler, T., and Dunay, I.R. (2017). Behavior of Neutrophil Granulocytes during Toxoplasma gondii Infection in the Central Nervous System. Frontiers in cellular and infection microbiology *7*, 259.

Blanchard, N., Dunay, I.R., and Schluter, D. (2015). Persistence of Toxoplasma gondii in the central nervous system: a fine-tuned balance between the parasite, the brain and the immune system. Parasite Immunol *37*, 150-158.

Blanchard, N., Gonzalez, F., Schaeffer, M., Joncker, N.T., Cheng, T., Shastri, A.J., Robey, E.A., and Shastri, N. (2008). Immunodominant, protective response to the parasite Toxoplasma gondii requires antigen processing in the endoplasmic reticulum. Nat Immunol *9*, 937-944.

Bonnart, C., Feuillet, G., Vasseur, V., Cenac, N., Vergnolle, N., and Blanchard, N. (2017). Protease-activated receptor 2 contributes to Toxoplasma gondii-mediated gut inflammation. Parasite Immunol *39*.

Bougdour, A., Maubon, D., Baldacci, P., Ortet, P., Bastien, O., Bouillon, A., Barale, J.C., Pelloux, H., Menard, R., and Hakimi, M.A. (2009). Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites. J Exp Med *206*, 953-966.

Boyle, J.P., Saeij, J.P., Cleary, M.D., and Boothroyd, J.C. (2006). Analysis of gene expression during development: lessons from the Apicomplexa. Microbes Infect *8*, 1623-1630.

Brown, C.R., Hunter, C.A., Estes, R.G., Beckmann, E., Forman, J., David, C., Remington, J.S., and McLeod, R. (1995). Definitive identification of a gene that confers resistance against Toxoplasma cyst burden and encephalitis. Immunology *85*, 419-428.

Buaillon, C., Guerrero, N.A., Cebrian, I., Blanie, S., Lopez, J., Bassot, E., Vasseur, V., Santi-Rocca, J., and Blanchard, N. (2017). MHC I presentation of Toxoplasma gondii immunodominant antigen does not require Sec22b and is regulated by antigen orientation at the vacuole membrane. Eur J Immunol *47*, 1160-1170.

Cabral, C.M., McGovern, K.E., MacDonald, W.R., Franco, J., and Koshy, A.A. (2017). Dissecting Amyloid Beta Deposition Using Distinct Strains of the Neurotropic Parasite Toxoplasma gondii as a Novel Tool. ASN Neuro *9*, 1759091417724915.

Cabral, C.M., Tuladhar, S., Dietrich, H.K., Nguyen, E., MacDonald, W.R., Trivedi, T., Devineni, A., and Koshy, A.A. (2016). Neurons are the Primary Target Cell for the Brain-Tropic Intracellular Parasite Toxoplasma gondii. PLoS pathogens *12*, e1005447.

Casanova, A., Blatche, M.C., Ferre, C.A., Martin, H., Gonzalez-Dunia, D., Nicu, L., and Larrieu, G. (2018). Self-Aligned Functionalization Approach to Order Neuronal Networks at the Single-Cell Level. Langmuir : the ACS journal of surfaces and colloids *34*, 6612-6620.

903 Casanova, E., Fehsenfeld, S., Mantamadiotis, T., Lemberger, T., Greiner, E., Stewart, A.F., and
904 Schutz, G. (2001). A CamKIIalpha iCre BAC allows brain-specific gene inactivation. Genesis *31*,
905 37-42.
906 Cebrian, C., Zucca, F.A., Mauri, P., Steinbeck, J.A., Studer, L., Scherzer, C.R., Kanter, E.,
907 Budhu, S., Mandelbaum, J., Vonsattel, J.P., *et al.* (2014). MHC-I expression renders
908 catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun *5*, 3633.
909 Chevalier, G., Suberbielle, E., Monnet, C., Duplan, V., Martin-Blondel, G., Farrugia, F., Le
910 Masson, G., Liblau, R., and Gonzalez-Dunia, D. (2011). Neurons are MHC class I-dependent
911 targets for CD8 T cells upon neurotropic viral infection. PLoS pathogens *7*, e1002393.
912 Chu, H.H., Chan, S.W., Gosling, J.P., Blanchard, N., Tsitsiklis, A., Lythe, G., Shastri, N.,
913 Molina-Paris, C., and Robey, E.A. (2016). Continuous Effector CD8(+) T Cell Production in a
914 Controlled Persistent Infection Is Sustained by a Proliferative Intermediate Population. Immunity
915 *45*, 159-171.
916 Colonna, M., and Butovsky, O. (2017). Microglia Function in the Central Nervous System
917 During Health and Neurodegeneration. Annu Rev Immunol *35*, 441-468.
918 Corriveau, R.A., Huh, G.S., and Shatz, C.J. (1998). Regulation of class I MHC gene expression
919 in the developing and mature CNS by neural activity. Neuron *21*, 505-520.
920 Di Liberto, G., Pantelyushin, S., Kreutzfeldt, M., Page, N., Musardo, S., Coras, R., Steinbach, K.,
921 Vincenti, I., Klimek, B., Lingner, T., *et al.* (2018). Neurons under T Cell Attack Coordinate
922 Phagocyte-Mediated Synaptic Stripping. Cell *175*, 458-471 e419.
923 Elmer, B.M., and McAllister, A.K. (2012). Major histocompatibility complex class I proteins in
924 brain development and plasticity. Trends in neurosciences *35*, 660-670.
925 Evans, G.A., Margulies, D.H., Shykind, B., Seidman, J.G., and Ozato, K. (1982). Exon shuffling:
926 mapping polymorphic determinants on hybrid mouse transplantation antigens. Nature *300*, 755-
927 757.
928 Feliu, V., Vasseur, V., Grover, H.S., Chu, H.H., Brown, M.J., Wang, J., Boyle, J.P., Robey, E.A.,
929 Shastri, N., and Blanchard, N. (2013). Location of the CD8 T Cell Epitope within the Antigenic
930 Precursor Determines Immunogenicity and Protection against the Toxoplasma gondii Parasite.
931 PLoS pathogens *9*, e1003449.
932 Ferguson, D.J., and Hutchison, W.M. (1987). The host-parasite relationship of Toxoplasma
933 gondii in the brains of chronically infected mice. Virchows Archiv. A, Pathological anatomy and
934 histopathology *411*, 39-43.
935 Fox, B.A., Falla, A., Rommereim, L.M., Tomita, T., Gigley, J.P., Mercier, C., Cesbron-Delauw,
936 M.F., Weiss, L.M., and Bzik, D.J. (2011). Type II Toxoplasma gondii KU80 knockout strains
937 enable functional analysis of genes required for cyst development and latent infection. Eukaryot
938 Cell *10*, 1193-1206.
939 Frickel, E.M., Sahoo, N., Hopp, J., Gubbels, M.J., Craver, M.P., Knoll, L.J., Ploegh, H.L., and
940 Grotenbreg, G.M. (2008). Parasite stage-specific recognition of endogenous Toxoplasma gondii-
941 derived CD8+ T cell epitopes. The Journal of infectious diseases *198*, 1625-1633.
942 Fuertes Marraco, S.A., Grosjean, F., Duval, A., Rosa, M., Lavanchy, C., Ashok, D., Haller, S.,
943 Otten, L.A., Steiner, Q.G., Descombes, P., *et al.* (2012). Novel murine dendritic cell lines: a
944 powerful auxiliary tool for dendritic cell research. Front Immunol *3*, 331.
945 Glynn, M.W., Elmer, B.M., Garay, P.A., Liu, X.B., Needleman, L.A., El-Sabeawy, F., and
946 McAllister, A.K. (2011). MHCI negatively regulates synapse density during the establishment of
947 cortical connections. Nature neuroscience *14*, 442-451.

948 Guo, M., Mishra, A., Buchanan, R.L., Dubey, J.P., Hill, D.E., Gamble, H.R., Jones, J.L., and
949 Pradhan, A.K. (2016). A Systematic Meta-Analysis of Toxoplasma gondii Prevalence in Food
950 Animals in the United States. Foodborne pathogens and disease *13*, 109-118.
951 Heneka, M.T., Carson, M.J., El Khoury, J., Landreth, G.E., Brosseron, F., Feinstein, D.L.,
952 Jacobs, A.H., Wyss-Coray, T., Vitorica, J., Ransohoff, R.M., *et al.* (2015). Neuroinflammation in
953 Alzheimer's disease. Lancet Neurol *14*, 388-405.
954 Herz, J., Johnson, K.R., and McGavern, D.B. (2015). Therapeutic antiviral T cells
955 noncytopathically clear persistently infected microglia after conversion into antigen-presenting
956 cells. Journal of Experimental Medicine *212*, 1153-1169.
957 Hidano, S., Randall, L.M., Dawson, L., Dietrich, H.K., Konradt, C., Klover, P.J., John, B., Harris,
958 T.H., Fang, Q., Turek, B., *et al.* (2016). STAT1 Signaling in Astrocytes Is Essential for Control
959 of Infection in the Central Nervous System. MBio *7*.
960 Huh, G.S., Boulanger, L.M., Du, H., Riquelme, P.A., Brotz, T.M., and Shatz, C.J. (2000).
961 Functional requirement for class I MHC in CNS development and plasticity. Science *290*, 2155-
962 2159.
963 Hwang, S., Cobb, D.A., Bhadra, R., Youngblood, B., and Khan, I.A. (2016). Blimp-1-mediated
964 CD4 T cell exhaustion causes CD8 T cell dysfunction during chronic toxoplasmosis. J Exp Med
965 *213*, 1799-1818.
966 John, B., Ricart, B., Tait Wojno, E.D., Harris, T.H., Randall, L.M., Christian, D.A., Gregg, B.,
967 De Almeida, D.M., Weninger, W., Hammer, D.A., and Hunter, C.A. (2011). Analysis of behavior
968 and trafficking of dendritic cells within the brain during toxoplasmic encephalitis. PLoS
969 pathogens *7*, e1002246.
970 Karttunen, J., Sanderson, S., and Shastri, N. (1992). Detection of rare antigen-presenting cells by
971 the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc
972 Natl Acad Sci U S A *89*, 6020-6024.
973 Kim, S.K., Karasov, A., and Boothroyd, J.C. (2007). Bradyzoite-specific surface antigen SRS9
974 plays a role in maintaining Toxoplasma gondii persistence in the brain and in host control of
975 parasite replication in the intestine. Infect Immun *75*, 1626-1634.
976 Klein, R.S., and Hunter, C.A. (2017). Protective and Pathological Immunity during Central
977 Nervous System Infections. Immunity *46*, 891-909.
978 Kreutzfeldt, M., Bergthaler, A., Fernandez, M., Bruck, W., Steinbach, K., Vorm, M., Coras, R.,
979 Blumcke, I., Bonilla, W.V., Fleige, A., *et al.* (2013). Neuroprotective intervention by interferon-
980 gamma blockade prevents CD8+ T cell-mediated dendrite and synapse loss. J Exp Med *210*,
981 2087-2103.
982 Malo, C.S., Huggins, M.A., Goddery, E.N., Tolcher, H.M.A., Renner, D.N., Jin, F., Hansen,
983 M.J., Pease, L.R., Pavelko, K.D., and Johnson, A.J. (2018). Non-equivalent antigen presenting
984 capabilities of dendritic cells and macrophages in generating brain-infiltrating CD8 (+) T cell
985 responses. Nat Commun *9*, 633.
986 McDole, J.R., Danzer, S.C., Pun, R.Y., Chen, Y., Johnson, H.L., Pirko, I., and Johnson, A.J.
987 (2010). Rapid formation of extended processes and engagement of Theiler's virus-infected
988 neurons by CNS-infiltrating CD8 T cells. Am J Pathol *177*, 1823-1833.
989 McManus, R.M., and Heneka, M.T. (2017). Role of neuroinflammation in neurodegeneration:
990 new insights. Alzheimer's research & therapy *9*, 14.
991 Melzer, T.C., Cranston, H.J., Weiss, L.M., and Halonen, S.K. (2010). Host Cell Preference of
992 Toxoplasma gondii Cysts in Murine Brain: A Confocal Study. J Neuroparasitology *1*.

Meuth, S.G., Herrmann, A.M., Simon, O.J., Siffrin, V., Melzer, N., Bittner, S., Meuth, P., Langer, H.F., Hallermann, S., Boldakowa, N., *et al.* (2009). Cytotoxic CD8+ T cell-neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death. The Journal of neuroscience : the official journal of the Society for Neuroscience *29*, 15397-15409.

Mohle, L., Israel, N., Paarmann, K., Krohn, M., Pietkiewicz, S., Muller, A., Lavrik, I.N., Buguliskis, J.S., Schott, B.H., Schluter, D., *et al.* (2016). Chronic Toxoplasma gondii infection enhances beta-amyloid phagocytosis and clearance by recruited monocytes. Acta neuropathologica communications *4*, 25.

O'Brien, C.A., Batista, S.J., Still, K.M., and Harris, T.H. (2019). IL-10 and ICOS Differentially Regulate T Cell Responses in the Brain during Chronic Toxoplasma gondii Infection. J Immunol *202*, 1755-1766.

O'Brien, C.A., Overall, C., Konradt, C., O'Hara Hall, A.C., Hayes, N.W., Wagage, S., John, B., Christian, D.A., Hunter, C.A., and Harris, T.H. (2017). CD11c-Expressing Cells Affect Regulatory T Cell Behavior in the Meninges during Central Nervous System Infection. J Immunol *198*, 4054-4061.

Ondounda, M., Ilozue, C., and Magne, C. (2016). Cerebro-meningeal infections in HIV-infected patients: a study of 116 cases in Libreville, Gabon. African health sciences *16*, 603-610.

Ozato, K., Evans, G.A., Shykind, B., Margulies, D.H., and Seidman, J.G. (1983). Hybrid H-2 histocompatibility gene products assign domains recognized by alloreactive T cells. Proc Natl Acad Sci U S A *80*, 2040-2043.

Ozato, K., Hansen, T.H., and Sachs, D.H. (1980). Monoclonal antibodies to mouse MHC antigens. II. Antibodies to the H-2Ld antigen, the products of a third polymorphic locus of the mouse major histocompatibility complex. J Immunol *125*, 2473-2477.

Pappas, G., Roussos, N., and Falagas, M.E. (2009). Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. International journal for parasitology *39*, 1385-1394.

Parlog, A., Harsan, L.A., Zagrebelsky, M., Weller, M., von Elverfeldt, D., Mawrin, C., Korte, M., and Dunay, I.R. (2014). Chronic murine toxoplasmosis is defined by subtle changes in neuronal connectivity. Disease models & mechanisms *7*, 459-469.

Perry, C.E., Gale, S.D., Erickson, L., Wilson, E., Nielsen, B., Kauwe, J., and Hedges, D.W. (2016). Seroprevalence and Serointensity of Latent Toxoplasma gondii in a Sample of Elderly Adults With and Without Alzheimer Disease. Alzheimer disease and associated disorders *30*, 123-126.

Rall, G.F., Mucke, L., and Oldstone, M.B. (1995). Consequences of cytotoxic T lymphocyte interaction with major histocompatibility complex class I-expressing neurons in vivo. J Exp Med *182*, 1201-1212.

Russo, M.V., and McGavern, D.B. (2015). Immune Surveillance of the CNS following Infection and Injury. Trends in immunology *36*, 637-650.

Sa, Q., Ochiai, E., Tiwari, A., Perkins, S., Mullins, J., Gehman, M., Huckle, W., Eyestone, W.H., Saunders, T.L., Shelton, B.J., and Suzuki, Y. (2015). Cutting Edge: IFN-gamma Produced by Brain-Resident Cells Is Crucial To Control Cerebral Infection with Toxoplasma gondii. J Immunol *195*, 796-800.

Sauer, B.M., Schmalstieg, W.F., and Howe, C.L. (2013). Axons are injured by antigen-specific CD8(+) T cells through a MHC class I- and granzyme B-dependent mechanism. Neurobiology of disease *59*, 194-205.
Schaeffer, M., Han, S.J., Chtanova, T., van Dooren, G.G., Herzmark, P., Chen, Y., Roysam, B., Striepen, B., and Robey, E.A. (2009). Dynamic imaging of T cell-parasite interactions in the brains of mice chronically infected with Toxoplasma gondii. J Immunol *182*, 6379-6393.
Stock, A.K., Dajkic, D., Kohling, H.L., von Heinegg, E.H., Fiedler, M., and Beste, C. (2017). Humans with latent toxoplasmosis display altered reward modulation of cognitive control. Sci Rep *7*, 10170.
Suzuki, Y., Wang, X., Jortner, B.S., Payne, L., Ni, Y., Michie, S.A., Xu, B., Kudo, T., and Perkins, S. (2010). Removal of Toxoplasma gondii cysts from the brain by perforin-mediated activity of CD8+ T cells. Am J Pathol *176*, 1607-1613.
Torrey, E.F., and Yolken, R.H. (2003). Toxoplasma gondii and schizophrenia. Emerg Infect Dis *9*, 1375-1380.
Vyas, A. (2015). Mechanisms of Host Behavioral Change in Toxoplasma gondii Rodent Association. PLoS pathogens *11*, e1004935.
Wang, X., Zhang, C., Szabo, G., and Sun, Q.Q. (2013). Distribution of CaMKIIalpha expression in the brain in vivo, studied by CaMKIIalpha-GFP mice. Brain research *1518*, 9-25.
Watts, E., Zhao, Y., Dhara, A., Eller, B., Patwardhan, A., and Sinai, A.P. (2015). Novel Approaches Reveal that Toxoplasma gondii Bradyzoites within Tissue Cysts Are Dynamic and Replicating Entities In Vivo. MBio *6*, e01155-01115.
Wilking, H., Thamm, M., Stark, K., Aebischer, T., and Seeber, F. (2016). Prevalence, incidence estimations, and risk factors of Toxoplasma gondii infection in Germany: a representative, cross-sectional, serological study. Sci Rep *6*, 22551.
Wilson, E.H., and Hunter, C.A. (2004). The role of astrocytes in the immunopathogenesis of toxoplasmic encephalitis. Int J Parasitol *34*, 543-548.
Wyman, C.P., Gale, S.D., Hedges-Muncy, A., Erickson, L.D., Wilson, E., and Hedges, D.W. (2017). Association between Toxoplasma gondii seropositivity and memory function in nondemented older adults. Neurobiology of aging *53*, 76-82.
Xie, L., and Yang, S.H. (2015). Interaction of astrocytes and T cells in physiological and pathological conditions. Brain research *1623*, 63-73.
Yshii, L.M., Gebauer, C.M., Pignolet, B., Maure, E., Queriault, C., Pierau, M., Saito, H., Suzuki, N., Brunner-Weinzierl, M., Bauer, J., and Liblau, R. (2016). CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain : a journal of neurology *139*, 2923-2934.
Zhang, Y.H., Chen, H., Chen, Y., Wang, L., Cai, Y.H., Li, M., Wen, H.Q., Du, J., An, R., Luo, Q.L., *et al.* (2014). Activated microglia contribute to neuronal apoptosis in Toxoplasmic encephalitis. Parasit Vectors *7*, 372.

Figure 1


a
Promoter:
Antigenic construct:
Parasite:
Tachyzoites (vacuole)
Bradyzoites (cyst)
GRA6
GRA6-OVA
GRA6
LEQLE SIINFEKL
Tg.pGRA6/ GRA6-OVA
TUBULIN
vacOVA
SAG1ΔGPI-OVA
LEQLE SIINFEKL
Tg.pTUB/ vacOVA
5 µm
10 µm
Tomato
GRA6-OVA
vacOVA
b
C57BL/6 (H-2b)
CBA (H-2k)
0
days
21
Brain Tg load
Inflammation
Infection:
Tg.Tomato
Tg.pGRA6/GRA6-OVA
Tg.pTUB/vacOVA
e
Myeloid cell gating strategy
SSC
FSC
FSC-A
Live/Dead
Ly6G
NK1.1
CD45
CD11b
Ly6C
CD45hi CD11b+ 'inf. myeloid cells'
Ly6Chi 'inflammatory monocytes'
CD45int CD11b+ 'microglia'
Brain cysts
c
C57BL/6
d
CBA
Cysts / brain (#)
p=0,003
p=0,028
p>0,99
p>0,99
p=0,83
p = 0,22
f
singlets live Ly6G- NK1.1-
Tg.Tomato
Tg.pGRA6/ GRA6-OVA
Tg.pTUB/vacOVA
Uninfected
9,7 ± 1,4%
5 ± 1,5%
8,2 ± 2,3%
2,6%
1,9 ± 0,5%
3,0 ± 1,0%
1,9 ± 0,7%
29,6%
CD45
CD11b
Inf. myeloid cells / microglia
CD45hi / CD45int ratio
p=0,007
p=0,12
p=0,97
g
Tg.Tomato
Tg.pGRA6/GRA6-OVA
Tg.pTUB/vacOVA
Uninfected
5X
20X inset
Iba1
h
singlets live Ly6G- NK1.1- CD45hi CD11b+
Tg.Tomato
Tg.pGRA6/ GRA6-OVA
Tg.pTUB/ vacOVA
50,7 ± 2,9%
37,2 ± 2,8%
45,2 ± 6,7%
Ly6C
CD11b
Inf. monocytes
Ly6Chi cells (#)
p=0,004
p=0,028
p>0,99
i
gated on live Ly6G- NK1.1- CD45hi CD11b+ Ly6Chi ('inf. monocytes')
MHC II
Uninfected
0%
Tg.Tomato
81,4 ± 5,5%
Tg.pGRA6/ GRA6-OVA
72,9 ± 2,9%
Tg.pTUB/ vacOVA
86,3 ± 4,2%
MHC II+ out of Ly6Chi (%)
p=0,17
p=0,004
p=0,61
j
Tg.Tomato
Tg.pGRA6/ GRA6-OVA
Tg.pTUB/ vacOVA
11,9 ± 2,7%
3,7 ± 0,3%
9,1 ± 1,7%
CD4
IFNγ
IFNγ production by CD4 T cells
IFNγ+ CD4+ T cells (#)
p=0,002
p=0,045
p>0,99

Figure 2


a
Promoter:
Antigenic construct:
Parasite:
none
Tg.GFP
GRA6
GRA6
LEQLE
SIINFEKL
Tg.pGRA6/
GRA6-OVA
SAG1
GRA6
LEQLE
SIINFEKL
Tg.pSAG1/
GRA6-OVA
b
GRA6-OVA expression in cysts
T.gondii &
cyst wall
GRA6-OVA
GRA2
Mean Fluorescence of
anti-SIINFEKL staining
p= 0,037
p= 0,003
p>0,99
c
MHC I presentation of GRA6-OVA by
tachyzoite-infected dendritic cells
Tg.GFP
Tg.pGRA6/GRA6-OVA
Tg.pSAG1/GRA6-OVA
B3Z T cell activation
(A595-A650 nm)
Tachyzoites / cell
d
C57BL/6
0
weeks
8
Infection:
Tg.GFP
Tg.pGRA6/GRA6-OVA
Tg.pSAG1/GRA6-OVA
CD8 T cell responses
Spleen & Brain
e
Spleen
Response to:
Tg.GFP
Tg.pGRA6/
GRA6-OVA
Tg.pSAG1/
GRA6-OVA
Uninfected
GRA6-OVA
(SIINFEKL)
Tgd057
(SVLAFRRL)
0,19 ± 0,1%
2,0 ± 0,6%
2,3 ± 1,6%
0,05 ± 0,0%
0,41 ± 0,1%
0,33 ± 0,1%
0,32 ± 0,1%
0,06 ± 0,01%
CD8
IFNγ
f
SIINFEKL restimulation
IFNγ+ CD8+ T cells (#)
p=0,049
p>0,99
p=0,01
g
SVLAFRRL restimulation
p=0,54
p>0,99
p=0,31
h
Brain
Response to:
Tg.GFP
Tg.pGRA6/
GRA6-OVA
Tg.pSAG1/
GRA6-OVA
Uninfected
GRA6-OVA
(SIINFEKL)
Tgd057
(SVLAFRRL)
1,1 ± 0,3%
12,8 ± 2,7%
13,2 ± 4,0%
0,28 ± 0,3%
1,7 ± 0,5%
1,3 ± 0,1%
1,5 ± 0,21%
0,00%
CD8
IFNγ
i
SIINFEKL restimulation
IFNγ+ CD8+ T cells (#)
p=0,049
p>0,99
p=0,01
j
SVLAFRRL restimulation
p=0,03
p=0,47
p=0,67


Figure 3
a
C57BL/6
0
weeks
8
Infection:
Tg.GFP
Tg.pGRA6/GRA6-OVA
Tg.pSAG1/GRA6-OVA
Brain Tg load
Brain inflammation
Brain cysts
B6 mice (H-2b)
b
Cysts / brain (#)
p=0,009
p>0,99
p=0,0003
Brain parasite DNA
c
B6 mice (H-2b)
Parasite genome / µg brain DNA
p=0,001
p>0,99
p=0,045
d
CBA mice (H-2k)
p>0,99
p>0,99
p>0,99
e
singlets live Ly6G- NK1.1-
Tg.GFP
Tg.pGRA6/GRA6-OVA
Tg.pSAG1/GRA6-OVA
Uninfected
10,3 ± 1,7%
7,5 ± 2,6%
7,6 ± 3,0%
4,6 ± 0,5%
3,2 ± 1,5%
6,6 ± 3,2%
9,7 ± 6,1%
35,4 ± 9,5%
CD45
CD11b
Microglia
CD45int CD11b+ (#)
p>0,99
p>0,99
p>0,99
f
Inf. myeloid cells / microglia
CD45hi / CD45lo ratio
p=0,027
p>0,99
p=0,006
Gated on live Ly6G- NK1.1- CD45int CD11b+ ('microglia')
g
CD86
Uninfected
881
Tg.GFP
1275 ± 82
Tg.pGRA6/GRA6-OVA
1003 ± 76
Tg.pSAG1/GRA6-OVA
957 ± 45
CD86 on microglia (Fold-increase/uninf.)
p=0,002
p>0,99
p=0,004
h
MHC II
368
2813 ± 55
1063 ± 352
1224 ± 352
MHC II on microglia (Fold-increase/uninf.)
p=0,001
p>0,99
p=0,0008
i
singlets live Ly6G- NK1.1- CD45hi CD11b+
Tg.GFP
Tg.pGRA6/GRA6-OVA
Tg.pSAG1/GRA6-OVA
45,8 ± 7,8%
33,1 ± 12,6%
41,41 ± 15,6%
Ly6C
CD11b
Inf. monocytes
Ly6Chi cells (#)
p=0,025
p>0,99
p=0,045
Infection:
Tg.GFP
Tg.pGRA6/GRA6-OVA
Tg.pSAG1/GRA6-OVA
Gated on live Ly6G- NK1.1- CD45hi CD11b+ Ly6Chi ('inf. monocytes')
j
CD86
Uninfected
1924
Tg.GFP
3669 ± 156
Tg.pGRA6/GRA6-OVA
2975 ± 459
Tg.pSAG1/GRA6-OVA
3150 ± 500
CD86 on Ly6Chi (Fold-increase/uninf.)
p=0,06
p>0,99
p=0,07
k
MHC II
0%
86,4 ± 5,4%
50,1 ± 18,3%
62,5 ± 27,2%
MHC II+ out of Ly6Chi (%)
p=0,001
p=0,47
p=0,05
l
singlets live
Tg.GFP
Tg.pGRA6/GRA6-OVA
Tg.pSAG1/GRA6-OVA
3,1 ± 1,1%
2,3 ± 1,1%
1,5 ± 0,6%
CD4
IFNγ
IFNγ production by CD4 T cells
IFNγ+ CD4+ T cells (#)
p=0,047
p>0,99
p=0,15
Infection:
Tg.GFP
Tg.pGRA6/GRA6-OVA
Tg.pSAG1/GRA6-OVA

Figure 4


a
C57BL/6
0
days
21
Infection:
Tg.Tomato
Tg.pGRA6/GRA6-OVA
Tg.pTUB/vacOVA
CD8 T cell responses
Spleen & brain
Spleen
b
Kb-SIINFEKL dextramer labeling
Tg.Tomato
Tg.pGRA6/ GRA6-OVA
Tg.pTUB/ vacOVA
0,56 ± 0,2%
5,8 ± 0,7%
4,78 ± 0,9%
CD8
Kb-SIINFEKL dextramer
Kb-SIINFEKL dex+ CD8+ T cells (#)
p=0,002
p=0,41
p=0,17
c
SIINFEKL restimulation
IFNγ+ CD8+ T cells (#)
p=0,009
p>0,99
p=0,05
Brain
d
Kb-SIINFEKL dextramer labeling
Tg.Tomato
Tg.pGRA6/ GRA6-OVA
Tg.pTUB/ vacOVA
1,3 ± 0,3%
15,8 ± 4,0%
16,0 ± 5,3%
CD8
Kb-SIINFEKL dextramer
Kb-SIINFEKL dex+ CD8+ T cells (#)
p=0,009
p=0,06
p>0,99
e
SIINFEKL restimulation
IFNγ+ CD8+ T cells (#)
p=0,01
p>0,99
p=0,05
f
TNFα / granzyme B / IFNγ production by brain-infiltrating OVA-specific CD8 T cells
Tg.pGRA6/ GRA6-OVA
Tg.pTUB/ vacOVA
CD8
IFNγ
TNFα
granzyme B
1,9 ± 0,3%
7,3 ± 1,7%
IFNγ+ TNFα+ granzyme B+ CD8+ T cells (#)
p=0,03
Tg.pGRA6/GRA6-OVA
Tg.pTUB/vacOVA

Figure 5


a
C57BL/6
embryo
Hippocampi
Days of neuron culture
0
4
8
11
12
13
plating
AraC
AraC
IFNγ
T. gondii
Infection rate
Antigen presentation


b
T. gondii
MAP2
GFAP
merge
Tg.pGRA6/
GRA6-OVA
Tg.pTUB/
vacOVA


c
Infection rate
T. gondii vacuoles
(# out of 24 fields)
60
40
20
0
Tg.pGRA6/
GRA6-OVA
Tg.pTUB/
vacOVA


d
MHC I presentation by
tachyzoite-infected primary neurons
B3Z activation
(X-gal+ cells per well)
200
150
100
50
0
Tg.pGRA6/
GRA6-OVA
Tg.pTUB/
vacOVA
Uninfected
10³
10⁴
10⁵
Tachyzoites / well

Figure 6


a
LdLox cassette: Ld gene with floxed exons 1-3
LoxP
LoxP
L
N
C1
C2
M
I1
I2
I3
XbaI
1.6 kb
XbaI
12 kb
b
H-2 Kb
B6
B6.LdLox
B6.H-2d
229 ± 4
349 ± 11
913 ± 48
241 ± 6
393 ± 5
775 ± 28
68 ± 8
122 ± 5
479 ± 11
T cells
B cells
DC
c
H-2 Ld
B6
B6.LdLox
B6.H-2d
38 ± 2
91 ± 6
202 ± 7
1859 ± 14
2699 ± 86
3449 ± 86
5412 ± 625
5450 ± 305
8056 ± 448
T cells
B cells
DC
d
B6
B6.LdLox
B6.H-2d
0
days
21
Infection:
Tg.pTUB/vacOVA
CD8 T cell responses
Parasite load
Spleen & brain
Restimulation with GRA6-derived HF10 peptide
e
Spleen
p=0,009
p= 0,56
p=0,004
IFNγ+ CD8+ T cells (#)
f
Brain
p=0,003
p=0,84
p<0,0001
IFNγ+ CD8+ T cells (#)
g
Brain cysts
p=0,003
p=0,04
p<0,0001
Cysts / brain (#)
B6
B6.LdLox
B6.H-2d
h
B6.LdLox
B6.CamK-Cre
MHC I on:
Neurons
Other cells
B6.LdLox.CamK-Cre-
Kb, Db, Ld
Kb, Db, Ld
B6.LdLox.CamK-Cre+
Kb, Db
Kb, Db, Ld
C57BL/6
Kb, Db
Kb, Db
i
B6.LdLox.CamK-Cre-
B6.LdLox.CamK-Cre+
C57BL/6
0
days
21
Tg
Brain T cell responses
Tg load
j
Brain cysts
p=0,006
p>0,99
p=0,07
Cysts / brain (#)
k
Brain parasite DNA
p=0,008
p>0,99
p=0,06
Parasite genome / µg brain DNA
l
CD8 T cell infiltration
p>0,99
p=0,34
p=0,18
CD8+ T cells (#)
m
B6.LdLox. CamK-Cre-
B6.LdLox. CamK-Cre+
C57BL/6
CD8
IFNγ
23,6 ± 3,6%
20,6 ± 2,7%
2,2 ± 0,4%
Restimulation with GRA6-derived HF10 peptide
p=0,67
p=0,17
p=0,006
IFNγ+ CD8+ T cells (#)


Early chronic (10-21 dpi)
Late chronic (> 21 dpi)
POOR parasite control
type II T. gondii
Infected neuron
Parasite burden in CNS
Inflammation in CNS (encephalitis)
+++
EFFICIENT parasite control
CD8
or
T. gondii + GRA6-OVA Ag
+
+
POOR parasite control
MHC I Ld-deficient neuron
CD8
T. gondii + GRA6 Ag
Other CNS cell type
CD8
++
LEGEND
Tachyzoites (Vacuole)
Bradyzoites (Cyst)
GRA6-OVA or GRA6 Ag
MHC I loaded with parasite-derived peptide
CD8
Parasite-specific CD8 T cell